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Abstract 
Clostridium difficile infection (CDI) is a complex infectious disease that is 
commonly associated with antibiotic use and disruption of the intestinal 
microbiota. The current therapies, metronidazole or vancomycin, are increasingly 
associated with high rates of treatment failure and recurrent disease. A proposed 
alternative to the current therapies is the repurposed drug auranofin. Auranofin was 
previously approved for the treatment of rheumatoid arthritis, and has recently been 
investigated as a treatment for a number of diseases including cancer, HIV, 
parasitic infections and bacterial infections including CDI. The mechanism by 
which auranofin exerts antimicrobial activity is through the inhibition of 
selenoprotein synthesis. Auranofin does this by limiting the bioavailability of 
selenium to C. difficile, forming a stable adduct with selenide. This prevents  
C. difficile from taking up the selenide, thus blocking the selenium metabolism 
pathways necessary for selenoprotein synthesis. The aim of this study was to 
further investigate auranofin as a treatment option for CDI. 
This study had two main areas of focus: firstly, the number and level of 
conservation of selenoproteins in the C. difficile genome, and secondly, the in vitro 
activity of auranofin on C. difficile. 
Selenoproteins are proteins that contain selenium in the form of selenocysteine.  
C. difficile uses selenoproteins in the reductive deamination of the amino acids 
glycine and proline. This is done by the glycine reductase and proline reductase 
pathways, respectively, both of which are energy conserving. Using in silico 
methods it was found that there were 86 genes for selenoproteins identified in the 
C. difficile 630 genome, 87.21% of these showed >95% conservation among 100 
C. difficile strains. The proteins identified had a wide variety of putative functions 
including metabolism, information storage and processing, cellular processes and 
signalling. The high number of selenoproteins and the high level of conservation 
among them suggests that selenium and selenoproteins may play an essential role 
in C. difficile metabolism, information storage and processing, cellular processes 
and signalling. This provides strong evidence supporting selenium targeted therapy 
for the treatment of CDI. 
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Previous investigations have demonstrated the mechanism by which auranofin 
inhibits selenium metabolism in C. difficile, and that this in turn inhibits bacterial 
growth. This study further investigated the growth inhibitory activity of auranofin. 
We focused on the growth, vegetative cell viability, sporulation and toxin 
production of C. difficile cultures treated with auranofin after the cultures reached 
stationary phase. The efficacy of auranofin was compared to that of the current 
therapies metronidazole and vancomycin. Finally, auranofin was tested in an in 
vivo model of CDI in a preliminary animal trial. These investigations demonstrated 
that auranofin has showed bactericidal activity at a concentration as low as 50 µM 
in vitro effectively reducing bacterial growth, vegetative cell viability and spore 
viability. Auranofin also prevented the cytotoxic effects of the C. difficile toxin 
TcdB on Vero cells, and a dose of 200 µg/ml was sufficient to prevent CDI in an 
in vivo mouse model without adverse side effects.  
In conclusion, auranofin has many properties that make it suitable to use to treat 
CDI. Its activity may be considered narrow spectrum and is not directed toward a 
cellular molecular target but rather an essential nutrient. Auranofin also has the 
ideal pharmacokinetics for treating a gastrointestinal infection. Furthermore, the in 
vitro data presented here strongly demonstrated its efficacy against C. difficile. 
Auranofin has the potential to be an ideal therapeutic option for the treatment of 
CDI. 
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1. Introduction 
1.1. Background and epidemiology 
Clostridium difficile is a Gram-positive, spore forming, anaerobic, pathogenic 
bacterium belonging to the genus clostridia. Other members of this genus include 
the pathogens C. perfringens, C. botulinum, and C. tetani1. C. difficile was first 
isolated from the faeces of healthy neonates in 19352 and was first recognised as a 
human pathogen responsible for diarrhoea and pseudomembranous colitis (PMC) 
in 19781,3. C. difficile infection (CDI) is the leading cause of hospital acquired 
gastrointestinal infection. Recent studies suggest that C. difficile is responsible for 
25% more nosocomial infections in the U.S. than methicillin-resistant 
Staphylococcus aureus (MRSA)4. In 2013 the Centre for Disease Control and 
Prevention (CDC) in the U.S. declared CDI an urgent public health threat due to its 
capability of causing widespread and difficult to treat disease and its contribution 
to antimicrobial resistance. There are two other pathogens in this threat level; 
Carbapenem-resistant Enterobacteriaceae (CRE) and drug resistant  
Neisseria gonorrhoea5. 
Symptoms of CDI range from mild, watery diarrhoea to more severe 
pseudomembranous colitis (colon only) or pseudomembranous enterocolitis (colon 
and intestine; collectively referred to as PMC)2,6,7. PMC is characterised by yellow 
grey patches containing inflammatory cells and cellular debris forming a 
pseudomembrane over the intestinal mucosa2. Other symptoms of CDI include loss 
of appetite, nausea, fever, leucocytosis and abdominal cramping. Serious 
complications of CDI are life threatening and include colonic ileus, toxic 
megacolon, intestinal perforation, sepsis and shock2,6,7. Chronic diarrhoea also puts 
patients at risk of dehydration, electrolyte disruption, renal failure, hypotension and 
systemic inflammatory response syndrome2,6. Some people are colonised with  
C. difficile, but are asymptomatic. While they have no symptoms, they can still 
shed spores, the transmissible element, thereby effectively spreading the infection. 
The incidence of CDI has been steadily rising since the year 2000. In the U.S., the 
number of CDI related hospital admissions has tripled2,8 to 450,000 cases  
annually4,5,9-11. This adds a significant burden to healthcare systems with the annual 
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cost of CDI in the U.S. estimated to be in excess of USD $1 billion4,5,10,12. There 
has also been an increase in the severity of disease associated with CDI2,3,6,13-17 
resulting in longer hospital stays, increased admission to the intensive care unit 
(ICU), more emergency interventions such as colectomy and a higher mortality 
rate8,15,18,19. It has been estimated that the number of CDI related deaths in the U.S. 
is as high as 15,000 annually11. 
Until the development of a national surveillance model for C. difficile in 2010 by 
the Australian Commission for Safety and Quality in Healthcare (ACSQH) there 
was very little active surveillance of CDI in Australia. The commencement of this 
surveillance model in 2010 produced the first nationwide profile of CDI in 
Australia. A 2-year study (2011 to 2012) identified 12,683 cases of CDI by 
surveying the laboratory diagnosis of CDI in 450 Australian public hospitals. This 
study also found the rate of CDI increased during the study by 26%11. 
Infection with C. difficile is facilitated by the ingestion of metabolically dormant 
spores4,10,12,20-24. If the intestinal microbiota has been altered or depleted i.e. by 
antibiotic use, then the environment in the gut will be suitable for vegetative cell 
growth and the spores will germinate. The vegetative form then colonises the gut 
mucosa, proliferates, producing more spores and the toxins, TcdA and TcdB, which 
are the primary virulence factors and cause the disease pathology25. Antibiotic use 
is associated with nearly all cases of CDI, with most patients having received 
antibiotics within the three months prior to the onset of disease symptoms2. Most 
antibiotics, in particular broad-spectrum antibiotics, have been implicated in CDI, 
with clindamycin, cephalosporin, and quinolones such as moxifloxacin posing the 
greatest risk26. 
The elderly have an increased risk of symptomatic infection with C. difficile 
because of their decreased humoral immunity. There is also a higher occurrence of 
disease in women compared to men which may be due to increased antibiotic 
prescribing for urinary tract infections (UTIs), particularly in older women27. Other 
risk factors include the number and severity of underlying conditions including, 
immunosuppressive therapy, chemotherapy, inflammatory bowel disease (IBD), 
Crohn’s disease, long hospital stays, admission to ICU, recent surgical procedures 
particularly gastrointestinal, nasogastric tube procedures, gastric acid suppressors, 
renal impairment, contact with CDI patients, HIV infection, prophylactic use of 
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antibiotics and the use of non-steroidal anti-inflammatory agents2,3,6,7,13,19,25,28. 
Although traditionally considered a hospital-associated infection, CDI is 
increasingly being recognised as a community-associated disease. There is 
evidence of increasing occurrence of CDI in persons previously considered to be 
low risk such as children, pregnant women and younger adults with no underlying 
diseases6,13,29,30. 
1.2. C. difficile infection, pathology, the intestinal microbiota and 
the immune response 
1.2.1. The intestinal microbiota 
The intestinal microbiota refers to the normal microbial inhabitants of the 
gastrointestinal tract31 and is highly beneficial to human health32,33. At birth the 
gastrointestinal tract is sterile with colonisation occurring rapidly in the post-
partum period. Mode of delivery (i.e. vaginal or caesarean section) and diet (i.e. 
breast milk or formula) play an important role in microbiota development32,33. 
There are thousands of individual species that could colonize the human gut and 
the composition of the intestinal microbiota varies considerably between 
individuals32-34. The majority of the intestinal microbiota is made up of obligate 
anaerobes from the phyla Bacteroidetes, Firmicutes and Actinobacteria. Less 
dominant phyla include Lentisphaera, Fusobacterium and Verrucomicrobia. The 
microbiota also includes viruses such as bacteriophages, archaea such as 
methanogens and eukaryotes such as Candida and Blastocystis34. 
The intestinal microbiota plays a role in the breakdown of polysaccharides into 
short chain fatty acids, driving oxygen and pH regulation, maintaining intestinal 
barrier integrity, mediating the host immune response, reducing gut mucosal 
inflammation and increasing protection against infection by enteric pathogens such 
as C. difficile3,32,34. The intestinal microbiota is also responsible for the synthesis 
of several beneficial compounds including the B vitamins, folic acid, biotin and 
vitamin K, and the metabolism of bile acid and cholesterol as well as potentially 
harmful substances, such as nitrosamines, heterocyclic acid amines and oxalate32. 
Colonisation resistance is the protection of the intestinal mucosa from colonisation 
by enteric pathogens4,32,33,35,36. The intestinal microbiota can prevent colonisation 
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by pathogens by competing for attachment sites on the mucosa, limiting the 
resources available for pathogens, producing antimicrobial compounds and by 
stimulating the host’s defences33,35. A disruption of intestinal microbiota, known as 
intestinal dysbiosis, will limit its effectiveness to protect the host against pathogens, 
giving opportunists such as C. difficile a chance to colonise, overpopulate the lower 
gastrointestinal tract and cause disease4,19,32,33,35-38. One of the roles the intestinal 
microbiota plays in protection against C. difficile is the de-conjugation of the bile 
acid taurocholate into taurine and cholate. Taurocholate is a germinant for  
C. difficile spores, which are able to survive passage through the stomach to the 
intestines, a journey that most vegetative cells do not survive. De-conjugation of 
the spore germinant protects the gut from this mode of infection23,39. 
Intestinal dysbiosis is the state where the composition of the intestinal microbiota 
has been shifted from the normal beneficial state to one that has a negative effect 
on human health32,33. Intestinal dysbiosis can be attributed to a number of CDI risk 
factors including inflammatory bowel disease, chemotherapy, use of proton pump 
inhibitors, advanced age and most notably antibiotic use19,31,35,40,41. Treatment with 
broad spectrum antibiotics decreases the diversity and richness of the intestinal 
microbiota, with decreases in the abundance of Firmicutes and Bifidobacteria and 
increases in Proteobacteria40. Intestinal dysbiosis increases the host’s susceptibility 
to CDI by altering several aspects of colonization resistance including the 
production of antimicrobials, competition for nutrients and space and bile acid 
metabolism. Further to this, intestinal dysbiosis may play a role in the severity of 
CDI as the intestinal microbiota plays an integral role in the host immune response. 
Intestinal dysbiosis may contribute to the attenuated immune response that is 
associated with severe CDI. 
1.2.2. Colonization of the intestinal epithelium 
The disruption of the intestinal microbiota and subsequent reduction in colonisation 
resistance creates an ideal environment for opportunistic C. difficile. The 
transmissible element is the spores, which are metabolically dormant, highly 
resilient and capable of causing widespread disease4,10,20,21,23,42-47. C. difficile 
produces spores when the environment no longer supports vegetative growth, such 
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as nutrient restriction, exposure to antibiotics or disinfectant4,21,22,43,46,48. The 
general sporulation cycle is outlined in Figure 1.1. 
 
 
Figure 1.1 Sporulation cycle.  
When the environmental conditions do not favour vegetative cell growth, the vegetative cell can 
undergo cell division to produce a metabolically dormant spore. Adapted from Fimlaid et al., 2013 
and Leggett et al., 2012 
 
Once formed and released, the spores are metabolically dormant and contain very 
few genomic transcripts43. The transcripts that are found in the dormant spores are 
a mixture of transcripts from late stage sporulation that were trapped in the spore 
and proteins that are required during the germination process43 including redox 
proteins that aid in detoxifying the environment during germination to provide the 
oxygen-sensitive vegetative cells an anaerobic environment43. 
C. difficile spores have a multilayered structure designed to protect the core, which 
contains DNA, RNA ribosomes and the previously mentioned transcripts and 
proteins21,22,43,46,49. The core is relatively dehydrated compared to the vegetative 
cell, allowing it to remain dormant and resistant to heat and chemicals21,43,46,49. The 
layers of the spore are outlined in Figure 1.221,43,46,49. 
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Figure 1.2: Layers of the C. difficile spore. 
The multilayered structure of the C. difficile spore is designed to protect the DNA containing core. 
Adapted from Leggett et al., 2012. 
 
Once ingested, the spores pass through the stomach to the intestine where, upon 
detecting favourable conditions such as the presence of taurocholate, they begin the 
germination process43. Upon germination there is a dramatic change in the 
regulation of many proteins. Among the upregulated genes are ABC-transporters 
to import metabolites, genes associated with DNA replication, cell division and 
stress response, ribosomal proteins, DNA directed RNA-polymerase, 
transcriptional regulators and protein translocation mechanisms50. Genes 
associated with amino acid metabolism, the flagella, chemotaxis and toxin are all 
down regulated indicating that the germinating spore is dedicating its energy and 
resources to rebuilding itself into a vegetative cell43. Once the germination process 
is complete, the vegetative cell then upregulates these genes to resume normal 
cellular functions such as metabolism, movement and toxin production43. 
1.2.3. Toxins and virulence 
The pathology of CDI is caused by the primary virulence factors, the toxins TcdA 
and TcdB. These toxins belong to the large Clostridial glycosylating toxin (CGT) 
family which includes C. sordellii lethal toxin (TcsL) and C. novyi α-toxin 
(TcnA)38,51,52. The two toxins, TcdA and TcdB, have highly similar amino acid 
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sequences, with the exception of the C-terminus. They each have four domains: the 
glucosyltransferase domain (GTD) at the N-terminus, the hydrophobic 
transmembrane domain (TD), the cysteine protease domain (CPD), and the cell-
binding domain (CBD) at the C-terminus51,52. 
The CBD is characterised by a repetitive peptide element called the combined 
repetitive oligopeptides (CROPs), which are solenoid-like structures that facilitate 
protein-protein and protein-carbohydrate binding to each of the toxins cell surface 
receptors. TcdA binds to glycoprotein 96 (gp96), a member of the heat shock 
protein family that is expressed on the apical surface and in the cytoplasm of human 
colonocytes. TcdB binds to chondroitin sulphate proteoglycan 4 (CSPG4), a high 
molecular weight melanoma associated antigen, that is highly expressed throughout 
the intestine51. 
Binding of the toxins to their respective cell receptors initiates clathrin-dependent 
endocytosis, which is outlined in Figure 1.3. Acidification of the endosomal 
compartment causes a conformational change in the toxin structure, exposing the 
TD which is able to form a pore in the endosomal membrane via cholesterol-
dependent mechanism. This allows the GTD to enter the cytosol. The CPD is then 
activated by the binding of inositol hexakisphosphate (InsP6), resulting in auto-
cleavage and release of the GTD51,52. 
The GTD acts on the guanosine triphosphate (GTP)-binding proteins Rho, Rac and 
Cdc42. GTD catalyses the attachment of a glucose residue from uridine 
diphosphate (UDP)-glucose to a conserved threonine amino acid on the target 
protein. This irreversible monoglucosylation renders the protein inactive leading to 
disordered cell signalling, disruption of the actin cytoskeleton, opening of tight 
junctions, depolarisation of the cell, cell rounding, apoptosis, decreased epithelial 
barrier function, accumulation of fluid, inflammation, and intestinal injury. TcdA 
is not essential for virulence but does play a role in disease. TcdB has been shown 
to be essential for virulence and is 10 times more potent than TcdA25,51,52. 
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Figure 1.3: Endosomal mediated entry of toxins into epithelial cells. 
1) The CBD at the C- terminus of the toxins TcdA and TcdB bind to surface receptors on the 
epithelial cells outer membrane. 
2) Once these surface receptors have been activated, an endosome forms around the toxins.  
3) The toxins undergo a conformation change inside the endosome. Toxin insertion into the 
endosomal membrane is facilitated by TD. The GTD enters the cytosol and is cleaved off by 
activation of CPD. GTD is released into the cytosol. 
4) The GTD acts on the Rho GTPases through the following interactions: a) Prevents cycling of 
Rho between the cytosol and the membrane, b) Inhibits Rho activation, c) Glycosylates Rho to block 
the active conformation of Rho and d) Blocks Rho/effector interaction. 
5) The inhibition of the Rho GTPases interferes with a number of downstream processes such as 
tight junctions, epithelial barrier, immune cell migration, superoxide production, cytokine 
production, immune cell signalling, phagocytosis and adhesion. 
Adapted from Carter, Rood and Lyras, 2010 and Papatheodorou et al. 2010. 
 
The genes for TcdA and TcdB (tcdA and tcdB respectively) are located within a 
19.6kb region of the genomic chromosome called the Pathogenicity Locus (PaLoc), 
along with three regulatory genes: tcdR, tcdC and tcdE. The PaLoc and its protein 
products are outlined in Figures 1.4 and 1.5. The product of tcdE is a small protein 
(TcdE) predicted to have three transmembrane domains and is likely a member of 
the class 1 holins. Holins are small membrane proteins that are typically associated 
with the terminal lysis of phage infected bacteria53. C. difficile TcdE is similar in 
structure to holins53,54 and plays a role in toxin release by creating a pore in the 
bacterial cell membrane24,52-58. 
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The positive regulatory gene tcdR is located upstream of tcdA and tcdB55 and 
encodes the alternate sigma factor TcdR. TcdR regulates toxin transcription by 
forming a complex with RNA polymerase that binds to the toxin promoter 
regions45,52,55,59-61. TcdR is repressed during exponential growth phase but is highly 
expressed during stationary phase to positively regulate the expression of TcdA, 
TcdB and TcdE as well as its own expression. 
The negative regulator tcdC transcribes in the opposite direction to the other four 
genes and encodes the anti-sigma factor TcdC52,59-61. TcdC negatively regulates 
transcription by destabilising the TcdR-RNA polymerase complex55,56,62-65. It is 
thought that TcdC sequesters TcdR, possibly by binding to it, preventing it from 
binding to RNA polymerase65. This prevents DNA polymerase from attaching to 
the promoter region of tcdA, tcdB and tcdE thereby preventing transcription and 
release of the toxins. Transcription of TcdC is high in early exponential growth 
phase and decreases as the cells enter stationary phase55,56,58,62-64. 
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Figure 1.4: Positive regulation of gene expression in the pathogenicity locus. 
Positive regulation of gene expression by the alternate sigma factor tcdR. By forming a complex 
with RNA polymerase, tcdR promotes expression of the toxin genes tcdA and tcdB as well as tcdE 
and itself. Adapted from Carter, Rood and Lyras, 2010; Dupuy et al., 2006; Lyras et al., 2009; and 
Tan, Wee and Song, 2001 
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Figure 1.5: Negative regulation of gene expression in the pathogenicity locus. 
Negative regulation of gene expression occurs when tcdC destabilises the connection between RNA 
polymerase and tcdR. Adapted from Carter, Rood and Lyras, 2010; Dupuy et al., 2006; Lyras et al., 
2009; and Tan, Wee and Song, 2001 
 
In addition to TcdA and TcdB, approximately 10% of C. difficile strains produce a 
third toxin, C. difficile transferase (CDT)66-68. This toxin belongs to the binary 
actin-ADP-ribosylating toxins, which includes the C. perfringens iota toxin,  
C. botulinum C2 toxin, C. spirioforme toxin (CS) and B. cereus vegetative 
insecticidal toxin (VIP). CDT consists of a 48kDa enzymatic protein (CDTa) and 
a 99kDa binding and translocating protein (CDTb) 66-68. The cell surface receptor 
for CDTb is lipolysis-stimulated lipoprotein receptor (LSR) which is highly 
expressed in the intestine. Monomeric CDTb binds to LSR and undergoes 
oligomerization to form a heptamer of CDTb. The whole receptor-toxin complex 
is then endocytosed. Acidification of the endosomal compartment causes a 
structural change of the heptameric CDTb into a pre-pore that can insert itself into 
the endosomal membrane, creating a pore that mediates entry of CDTa into the 
cytosol. CDTa modifies actin to inhibit polymerization, leading to a decrease in the 
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cortical actin cytoskeleton resulting in the formation of microtubule protrusions 
which extend the cell surface. These microtubule protrusions form a dense 
extracellular network that can enhance bacterial adherence, thus facilitating 
colonisation66-69. 
1.2.4. The host immune response 
The immune response caused by C. difficile toxins plays an important role in 
regulating the disease progression of CDI. An insufficient immune response can 
result in an overwhelming infection, while too much of a response can exacerbate 
the intestinal injury caused by the toxins70-72. Asymptomatic carriers will 
experience an early increase in serum immunoglobulin (Ig) G antibodies against 
TcdA. Although other antigens and toxins elicit an immune response, it is the 
response to TcdA that plays a role in disease severity and recurrence. Patients who 
have an initial episode and develop an early increase in IgM antibodies against 
TcdA are unlikely to have a recurrent episode. Patients who experience multiple 
recurrences have very low serum levels of both IgG and IgM antibodies against 
TcdA70. 
The cellular stress caused by the toxins triggers the secretion of pro-inflammatory 
cytokines and expression of leukocyte adhesion molecules which facilitate 
neutrophil infiltration to the site of infection. Neutrophils are the first line of 
defence against pathogenic bacteria and can release bactericidal reactive oxygen 
intermediates, and directly phagocytose the bacteria. Neutrophils also release pro-
inflammatory cytokines and chemokines leading to an increased neutrophil 
response. An intense neutrophil response has been associated with increased 
severity of disease due to off-target effects that lead to tissue damage and 
pseudomembranous colitis73. It is likely that the intestinal dysbiosis that made the 
host susceptible to infection also contributes to the unbalanced immune response 
that contributes to the pathology of CDI33. 
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1.3. Risk to public health 
1.3.1. Sources 
Historically CDI has been predominantly a heath care associated infection. As 
previously discussed, C. difficile spores are a source of contamination in the 
hospital environment, able to survive for many months due to their resistance to 
cleaning products such as hospital disinfectants and alcohols74,75. The most 
commonly identified sources within the hospital environment include patients with 
symptomatic C. difficile, contaminated surfaces, carpets and soft furnishings, as 
well as the hands of healthcare workers74-76. Often overlooked as a source within 
the hospital environment and in the community, are asymptomatic carriers74,77. 
These are persons who have been exposed to and colonised by C. difficile but do 
not display any symptoms of disease. It is estimated that asymptomatic carriage in 
the community ranges from 0-17% of healthy adults50,78 and can be as high as 50% 
in hospitals and aged care facilities populations6. It is thought that asymptomatic 
carriers may be an important reservoir for this disease6,50. 
The number of CDI cases reported from community sources is growing, with the 
proportion of community acquired cases ranging from 15-44% of all cases in the 
U.S. and Europe79. C. difficile has been found in a variety of environmental samples 
including water, soil and animal faeces, as well as a number of food sources 
suggesting that C. difficile may be transmitted as a food-borne pathogen78,80. 
Studies conducted in Europe, Canada, the U.S. and Australia have found C. difficile 
spores in ground beef, pork, turkey, raw diet for dogs and cats as well as fruit and 
vegetable sources including ready-to-eat salads7,78,80-84. The contamination of 
meats with C. difficile could occur from faecal or environmental contamination 
during processing or while the animal is still alive. C. difficile has been shown to 
be quite prevalent on pig farms, isolated from pig faeces and the muscle tissue of 
rodents from these farms85. 
There have only been a few studies in the diversity of C. difficile in animals and 
the overlap of these strains with those found in humans86-88. A study in the 
Netherlands found ribotype 078 was particularly prominent on pig farms, and that 
rodents could play a role in transmission between farms89. Another study looking 
at C. difficile in Australian cattle found that 56% of calves less than 7 days old, 
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3.8% of calves aged 2 to 6 months and 1.8% of adult cattle were colonised with  
C. difficile. The ribotypes found were 002, 014, 033, 056, 064, 087, 103, 126, 127 
and 137, along with 11 that could not be identified86. It is interesting that ribotype 
064 was isolated as it is known to cause disease in humans but is not typically 
associated with animals. Keel et al. performed ribotyping on C. difficile isolates 
from bovine, equine, canine and human sources and found that there was some 
overlap in human and zoonotic C. difficile. Overlapping ribotypes include 001, 002, 
010, 012, 014, 015, 020, 078 and 12679. 
1.3.2. Hypervirulent strains 
The increase in occurrence and severity of CDI is due in part to the emergence of 
hypervirulent strains such as the increasingly endemic ribotype 027 and the 
zoonotic ribotype 078. Ribotype 027 has been implicated in a number of hospital 
outbreaks in Canada, the U.S. and Europe and there have been isolated cases in 
Asia, Central America and Australia2,26,90. This ribotype is associated with more 
severe disease, resistance to antibiotics such as fluoroquinolones, a higher rate of 
treatment failure and increased mortality. Ribotype 027 has a greater potential for 
toxin production due to mutations in the toxin regulatory genes2,26,91. This increase 
in toxin production is thought to contribute to the increased virulence of this 
ribotype. 
Ribotype 078 has zoonotic associations and is also considered to be hypervirulent. 
It is commonly found in neonatal pigs88 and although transmission from pigs to 
humans has not been established, it is possible that contaminated meat products are 
a source of community acquired CDI, with rodents being a potential vector88. 
1.3.3. Recurrent disease 
The economic burden of CDI is largely due to recurrent disease92. Recurrent CDI 
is disease that initially responds to antibiotic therapy but recurs after treatment has 
been completed. This should not be confused with refractory CDI, which is an 
initial failure to respond to antibiotic therapy93. Recurrent CDI can be very serious 
and difficult to treat, often requiring prolonged treatment with antibiotics94. 
Recurrence could indicate ongoing intestinal dysbiosis, that the initial treatment 
merely suppressed the infection rather than clearing it, or that there are residual 
spores present in the gastrointestinal tract that are resistant to the antibiotic therapy. 
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After initial infection 15-30% of patients will have recurrent CDI. A patient’s risk 
of recurrent CDI increases with each episode. After the initial episode, the risk of 
recurrence is approximately 20%. After the first recurrence, the risk increases to 
40%, and then increases to 60% after two or more recurrences92-94. 
1.3.4. Antibiotic resistance 
C. difficile has a variety of mechanisms for antibiotic resistance, including drug 
inactivation, target modification and efflux pumps. Table 1.1 provides an overview 
of antimicrobial resistance mechanisms in C. difficile. Resistance to 
cephalosporins, clindamycin, fluoroquinolones, β-lactams, macrolides, 
lincosamides and Streptogramin B classes of antibiotics has been well 
documented95-98. Reports of resistance to vancomycin and metronidazole are cause 
for concern98-100 since they are the antibiotics currently used to treat CDI. A study 
in Spain in 2002 reported that 3.1% of their isolates had intermediate resistance to 
vancomycin and 6.3% had resistance to metronidazole99. 
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Table 1.1: Mechanisms of antibiotic resistance in C. difficile. 
Adapted from Harmvoravongchai et al. 2017 
Type of resistance Antibiotic Mechanism, proteins (genes) 
Drug inactivation 
• Antibiotic degradation 
Β-lactams Hydrolyse β-lactam ring. Β-lactamases 
(CD034, CD0458, CD0464, CD0527, 
CD0655, CD0829, CD1802, CD2742, 
CD3651) 
• Antibiotic 
modification 
Chloramphenicol 
(CHL) 
Adds acetyl group to CHL, prevents 
binding to 50S ribosomal subunit. CHL 
acetyltransferase (catD) Tn4453a and 
Tn4453b 
• Prevention of 
antibiotic activation 
and detoxification 
Metronidazole 
(MTZ) 
• Disruption of iron homeostasis 
prevents activity of redox proteins, 
prevents reduction of MTZ 
• Convert MTZ to non-toxic 
aminomidazole, NimB homologue. 
Target modification 
• Target methylation 
Macrolides, 
lincosamides, 
streptogramin B 
Methylation of 50S ribosomal subunit, 
ERY ribosomal methylase B (ermB) 
Tn5398, Tn6194 and Tn6215 
Linezolid Methylation of 23S rRNA ribosomal 
subunit, rRNA methyltransferase (cfr) 
• Target mutation Fluoroquinolones Mutation in DNA  gyrase results in 
conformation change of target to prevent 
drug binding (gyrA or gyrB) 
Rifamycins Mutation in β-subunit RNA polymerase 
(RNAP; rpB) 
Fidaxomicin Mutation in RNAP-promoter complex 
(rpoB or rpoC) 
Fusidic acid Mutation in elongation factor G (EF-G) 
Vancomycin* Mutation in N-
acetylglucosaminyltransferase (murG) 
prevents drug binding peptidoglycan 
precursor 
• Target protection Tetracycline 
(TET) 
Prevention of TET binding to 30S 
ribosomal subunit by ribosome 
protection protein. 
Efflux pumps: Secondary 
multidrug transporters 
• Major facilitator 
family (MFS) 
 
 
Erythromycin 
(ERY) 
 
 
Clostridial Cme protein 
• Multidrug and toxic 
compound extrusion 
(MATE) 
Norfloxacin and 
ciprofloxacin 
Sodium-dependent efflux pump (cdeA) 
*Vancomycin resistance mechanisms are not fully determined 
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Although resistance mechanisms against vancomycin have not been fully 
determined, there have been studies that explored some possibilities. One study 
proposed an amino acid mutation in N-acetylglucosaminyltransferase (MurG) 
confers resistance by target mutation98. Another study by Sebaihia et al. reported 
finding genes in the genome of the strain C. difficile 630 that were very similar to 
the vancomycin genes encoding VanG-type resistance in Enterococcus faecalis, 
however C. difficile 630 shows no in vitro resistance to vancomycin63. It is possible 
that these genes are non-function or inactive in C. difficile 630, but are contributing 
to vancomycin resistance in other strains. 
Metronidazole resistance in C. difficile has been observed to be heterogenic, 
indicating that this type of resistance could be multifactorial98-100. Metronidazole 
enters the bacterial cell in an inactive form that needs to be reduced into its active 
form by redox proteins such as pyruvate:ferredoxin oxidoreductases, 
pyruvate:flavoredoxins or thioredoxin and thioredoxin reductases. Once active, 
metronidazole binds non-specifically to the bacterial DNA causing strand 
breakages that lead to cell death. Iron is a vital component of these redox proteins, 
so disrupting cellular iron homeostasis, such as a reduction in ferric uptake, could 
reduce the susceptibility of C. difficile to metronidazole98. Another catalyst to 
bypassing metronidazole activation in C. difficile is a putative 5-nitromidazole 
reductase (NimB) homologue. NimB converts metronidazole into aminomidazole 
which is a non-toxic compound. C. difficile strains with resistance to metronidazole 
have shown up to a 3-fold increase in NimB homologue expression compared to 
the wild type98. 
Other factors contributing to decreased susceptibility to metronidazole and 
vancomycin is the ability C. difficile has to form biofilms and spores. Biofilms are 
communities of bacteria within a polymeric matrix and are formed during chronic 
infection. Resistance to vancomycin is 12-fold higher in biofilm communities of  
C. difficile than it is in planktonic (non-biofilm) C. difficile. Resistance to 
metronidazole is 100-fold higher in biofilm communities than it is in planktonic  
C. difficile98. C. difficile spores are intrinsically resistant to antimicrobial therapy, 
including vancomycin and metronidazole, a factor that contributes to recurrent and 
refractory CDI98. 
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1.4. Current and emerging therapies 
1.4.1. Diagnosis and treatment guidelines 
The current Australasian Society for Infectious Diseases (ASID) guidelines for the 
diagnosis of CDI recommend that diagnostic testing should be performed on 
unformed stools from all patients hospitalised for greater than 72 hours for 
toxigenic C. difficile. Screening tests for toxigenic C. difficile should be highly 
sensitive (>90%) and laboratories need to use a testing algorithm that is highly 
specific. Diagnostic testing should not be performed on patients who are 
asymptomatic or minimally symptomatic, have formed or soft stools, and who have 
diarrhoea that is associated with laxative use. Re-testing of patients as a test of cure 
is also not recommended93. 
Treatment guidelines still recommend metronidazole for a mild to moderate initial 
episode CDI at 400 mg three times daily for 10 days, and vancomycin for a 
refractory initial episode or severe CDI at 125 mg four times daily for 10 days. A 
vancomycin taper is recommended for treatment of recurrent CDI. Fidaxomicin is 
not recommended as a first line therapy, instead should be reserved for refractory 
or recurrent CDI that has not responded to vancomycin. Further recurrence and 
treatment failure warrants consideration of faecal microbiota transplant (FMT)93. 
1.4.2. Antibiotics 
Antibiotics routinely recommended for CDI treatment are metronidazole and 
vancomycin, with newer or alternate antibiotics such as fidaxomicin, tigecycline, 
and rifaximin suggested as options for refractory cases of CDI that have failed to 
respond to vancomycin93. There are also a number of emerging antibiotics that are 
currently undergoing clinical and pre-clinical trials including surotomycin, LFF571 
and ridinilazole101. 
Metronidazole is a broad-spectrum, small molecule nitroimidazole antibiotic 
(Azoles class)102. Once reduced to its active form, metronidazole targets DNA102 
and inhibits cellular enzymatic functions103. Metronidazole is highly absorbed (up 
to 80%) so only low concentrations are reached in the gastrointestinal tract104-106. 
Metronidazole is preferred for mild-moderate disease as it is inexpensive and has a 
reduced risk of inducing vancomycin resistant bacteria such as vancomycin 
resistant enterococci (VRE)93,107. It cannot be used to treat chronic infections as 
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long-term use could result in cumulative neurotoxicity. Metronidazole has been 
shown to be inferior to vancomycin in the treatment of CDI, particularly severe 
cases108, and subinhibitory concentrations have been shown to increase toxin 
production and sporulation109. 
Vancomycin is a broad-spectrum glycopeptide antibiotic102. It is slow acting110 and 
kills rapidly growing C. difficile by inhibiting the later stages of peptidoglycan 
biosynthesis102. Oral vancomycin is recommended for severe CDI as it has superior 
efficacy, good pharmacokinetics (poorly absorbed) and has less side effects than 
metronidazole105,108. Vancomycin use does increase the risk of acquiring 
vancomycin-resistant organisms such as VRE. Vancomycin is able to suppress 
spore formation110, but is ineffective against already formed spores108 and 
subinhibitory concentrations increase toxin production109. There is also evidence 
that subinhibitory concentrations of vancomycin can increase the number of spores 
produced by some strains of C. difficile111. 
Vancomycin and metronidazole are becoming less effective in their treatment of 
CDI. There are continual reports of failure of these therapies, with failure as high 
as 38%4,112,113. The high failure rates and potential for antibiotic resistance against 
these current therapies are cause for concern and highlight the need for new 
effective therapies. 
Fidaxomicin is a macrocyclic class antibiotic that exhibits narrow-spectrum 
activity113-116. It inhibits DNA transcription by targeting the bacterial RNA 
polymerase102,116,117. Fidaxomicin is minimally absorbed and has limited activity 
against components of the normal gut flora114-116 Clinical cure rates with 
fidaxomicin are similar to those of vancomycin, but the rate of recurrence is 
significantly lower. The risk of recurrence when infected with hypervirulent 
ribotypes such as ribotype 027 is the same as that of vancomycin116. There is 
evidence to suggest that fidaxomicin can also prevent spore germination108. 
Tigecycline is a broad-spectrum glycycline class antibiotic that inhibits protein 
synthesis. It has strong activity against C. difficile, does not increase toxin 
production and is capable of reducing spore viability109. Rifaximin is a synthetic 
analogue of rifamycin, a broad-spectrum ansamycin class antibiotic. Rifaximin is 
primarily used for the treatment of traveller’s diarrhoea due to its effectiveness 
against several Gram-positive and Gram-negative bacteria. It is poorly absorbed 
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and has no systemic adverse events associated with its use. Rifaximin acts by 
inhibiting RNA synthesis and has good activity against C. difficile, however it may 
be too disruptive of the intestinal microbiota to prevent recurrent CDI118,119. 
Surotomycin is a narrow-spectrum cyclic lipopeptide antibiotic that is currently 
undergoing Phase III clinical trials. It is minimally absorbed and demonstrated to 
have dose-dependent bactericidal activity against C. difficile101. Surotomycin is 
chemically and structurally similar to daptomycin, which targets the bacterial 
membrane102. Surotomycin acts by depolarising the bacterial membrane which 
leads to a loss of proton gradient and cell death103. Ridinilazole is a narrow-
spectrum, first-in class antibiotic that is poorly absorbed106. It has demonstrated 
good activity in vitro and in an in vivo hamster model120 and has been shown to 
have a good safety and tolerability profile in Phase I clinical trials106. Ridinilazole 
reduces C. difficile vegetative cells and reduces C. difficile TcdA and TcdB 
production120 and has little antimicrobial activity against intestinal microbiota106. 
The mechanism of action for this antibiotic are not well understood120. LFF571 is 
a semisynthetic thiopeptide antibiotic currently undergoing Phase I clinical trials. 
LFF571 has shown good efficacy in vitro121,122 and in an in vivo golden hamster 
model, and has been shown to be safe and well tolerated in Phase I clinical trials122. 
It is poorly absorbed with limited systemic exposure and high faecal 
concentrations122. 
1.4.3. Faecal microbiota transplant (FMT) 
Faecal microbiota transplant (FMT) treats intestinal dysbiosis, and thereby 
recurrent CDI, by restoring the intestinal microbiota to a healthy state30,93,123-127. 
This is done by implanting faecal material, either donated or synthetic, into the 
distal colon of the gastrointestinal tract123,126,127. Once the intestinal microbiota has 
been re-established, microbiota functions such as metabolism, immune response 
modulation and colonization resistance are also restored123. FMT has been proven 
to be fast and effective at resolving recurrent CDI, with worldwide success rates of 
up to 90% being reported93,124,125,127-131. 
FMT is typically performed using fresh donated faeces from a healthy  
donor119,123-125,127,132. Fresh stool is generally preferred since it is considered to have 
the most viable organisms, there are also a number of risks that need to be 
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addressed. One of the biggest risks associated with FMT is the introduction of new 
pathogens47 and donors need to be screened for the pathogens in Table 1.2 below. 
This screening process is expensive, delays treatment and there is still a risk of 
transmitting pathogens that are either outside the period of detectability or for 
which diagnostic tests are unavailable129. Donors should also have had no 
antibiotics in the past 3 months, no gastrointestinal symptoms, immune disorders 
or other diseases outlined in Table 1.2, as well as no intravenous drug use, high-
risk sexual behaviours, tattoos, body piercings in the past 6 months and no history 
of incarceration47. There are also ethical considerations that need to be accounted 
for, such as coercion and confidentiality132. These risks and ethical concerns have 
prompted studies on the viability of frozen stool banks using anonymous volunteer 
donors. These studies determined that FMT using stool frozen less than 2 months 
is as clinically effective as fresh samples for recurrent CDI132,133, and frozen stool 
stored in 10% glycerol for 2-10 months has a first dose efficacy of 88%, and a 
second-dose efficacy of 100%132. Frozen stool banks could be an effective and 
reliable way to standardize donor stool processing, screen for pathogens and allow 
stool to be on demand for clinicians3,132,133. 
 
Table 1.2: Donor screening for faecal microbiota transplant. 
Pathogen screening Medical/disease screening 
• Hepatitis A, B and C 
• HIV 
• Syphilis 
• Clostridium difficile 
• Giardia 
• Rotavirus 
• Cryptosporidium 
• Cyclospora 
• Isopoda 
• Ova parasites 
• Shiga toxin-producing E. coli 
• Salmonella 
• Shigella 
• Yersinia 
• Campylobactor 
• Non-cholera vibrio 
• Plesiomonas 
• Aeromonas 
• History of diarrhoea 
• History of constipation 
• Inflammatory bowel disease 
• Irritable bowel syndrome 
• Immune disorders 
• Concurrent immunosuppressive agents 
• Malignancy 
• Diabetes mellitus type II 
• Metabolic syndromes 
• Major gastrointestinal surgery 
• Chronic pain syndromes 
• Autoimmune disorders 
 
 
There is a lack of standardization of FMT protocols. Delivery of the faecal material 
can be via colonoscopy, nasogastric tube, retention enema or orally delivered 
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encapsulated stool126. Different methods of delivery have different levels of 
efficacy, and associated risks. Methods such as colonoscopy and nasogastric tube 
have an efficacy of 80%-90%129, but have higher risks associated with them 
including infection, abdominal pain, discomfort, or bleeding95. Colonoscopy also 
presents the risk of bowel perforation95. Lower risk methods such as retention 
enema and oral encapsulation FMT have a significantly lower first-dose efficacy 
of 50%-70%129,134. A study by Khanna et al. found that the low efficacy of oral 
encapsulated FMT can be improved by using “synthetic” faeces. Named SER-109, 
this faeces alternative is composed of approximately 50 species of Firmicutes 
spores, one of the dominant phyla in a healthy intestinal microbiota, which were 
derived from the stool specimens of healthy donors. This treatment is based on the 
hypothesis that spore-forming organisms would compete with C. difficile for 
essential nutrients, and that the ethanol preparation would reduce the risk of 
transmitting other pathogens. This study found that SER-109 achieved clinical 
resolution of recurrent CDI in 96.7% of patients and resulted in rapid 
diversification of the intestinal microbiota129. 
The risks, strict donor screening requirements, invasiveness of the procedure and 
the perceived unpleasantness associated with FMT means that it is typically 
reserved as a treatment for severe recurrent or refractory CDI, rather than as routine 
therapy. A study investigating patient attitudes to FMT found that although most 
FMT patients were satisfied with the outcome of FMT, they acknowledge that they 
only agreed to the procedure because they were desperate for a cure127. Most 
patients find the procedure unappealing and experience feelings of embarrassment 
and discomfort when discussing FMT with their doctor and donor. 
1.4.4. Probiotics 
Probiotics are live bacteria or yeast which confer a health benefit to the host when 
they are consumed in adequate amounts. A number of different approaches have 
been investigated for the use of probiotics as a therapeutic or preventative method 
in the management of CDI. Commonly investigated probiotics for prevention of 
CDI include lactic acid bacteria such as Lactococcus and Lactobacillus spp. and 
the yeast Sacharomyces boulardii. 
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Lactic acid bacteria play critical roles as commensals in the gastrointestinal tract. 
They are ideal candidates for probiotics as they are able to survive transit through 
the stomach, can adhere to the intestinal epithelium, have immunomodulatory 
properties and are safe to consume in the quantity required to confer health 
benefits135. There have been a number of investigations into the role of 
Lactobacillus spp as probiotics. L. delbrueckii, have been shown to inhibit  
C. difficile adhesion to Caco-2 cells and reduce the cytotoxic effects of TcdA and 
TcdB136. L. casei, which was shown to suppress interleukin (IL)-8 production in  
C. difficile stimulated HT-29 cells136. L. rhamnosus, which was also able to inhibit 
C. difficile adherence to Caco-2 cells137 and suppress IL-8 production136 as well as 
induce immunocompetent cells to produce cytokines including IL-10, IL-12, tumor 
necrosis factor (TNF)-α and interferon (IFN)-γ. The cytokines IL-12 and IFN-γ are 
implicated in innate defence mechanisms in response to bacteria137. Lactococcus 
lactis has been used as a live delivery vehicle for a C. difficile vaccine. L. lactis 
modified to express the binding domains of TcdA and TcdB given orally or 
subcutaneously triggered an immune response against TcdA and TcdB in vivo. This 
immune response protected the animals from CDI and recurrent CDI135. 
S. boulardii secretes a protease that interferes with the binding of TcdA and TcdB 
to the receptor on the surface of human colonic epithelial cells. It has been 
demonstrated that S. boulardii significantly reduces recurrent episodes of CDI 
when used in combination with metronidazole or vancomycin136. 
Another approach to preventing CDI through the use of probiotics is non-toxigenic 
C. difficile. Colonizing the host with non-toxigenic C. difficile follows the 
colonization competition hypothesis, where the non-toxigenic C. difficile prevents 
the toxigenic C. difficile from colonizing the distal colon by occupying the same 
ecologic niche, thereby preventing disease. Candidates for this type of probiotic 
therapy include C. difficile strain M3, which has been shown to be well tolerated, 
able to colonize the gastrointestinal tract and significantly reduce recurrent CDI, as 
well as C. difficile strain CD37, which is a poor sporulator and provided significant 
protection against toxigenic C. difficile in a mouse model of CDI. Although these 
studies were promising, non-toxigenic C. difficile should be approached with 
caution as there is the possibility of non-toxigenic C. difficile converting to 
toxigenic strains138. This has not been reported in vivo, but has been demonstrated 
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by Brouwer et al. in vitro, who were able to observe the horizontal transfer of the 
pathogenicity locus from a toxigenic strain to a non-toxigenic strain139. 
1.4.5. Vaccines and antibodies 
The immune response to TcdA and TcdB has been shown to play a significant role 
in disease severity and the risk of recurrence140-144. There is evidence that high 
concentrations of immunoglobulin (Ig) G to TcdA is associated with asymptomatic 
carriage, while a low immune response is associated with increased risk of 
recurrent CDI143. Similarly, the presence of high serum IgG to TcdB is capable of 
neutralizing the cytotoxic activity of TcdB and correlated to clinical recovery from 
CDI without relapse143. The importance of antibodies against the toxins in 
protection from CDI has led to the development of immune based therapies 
primarily aimed at preventing recurrent C. difficile. 
Karczewski et al. tested the efficacy of a vaccine consisting of two separately 
expressed recombinant fragments of TcdB combined with full-length, 
formaldehyde inactivated TcdA in an in vivo hamster challenge model, and found 
that the hamsters developed a high titre of neutralizing antibodies that last 
approximately 3 months145. A toxoid vaccine developed by Sheldon et al. is 
currently in Phase II clinical trials, and has proven to be safe and well tolerated 
with a strong increase in neutralizing antibodies after 2-3 doses140. A recombinant 
fusion protein (CLA84) containing portions of the receptor binding domains from 
TcdA and TcdB has demonstrated to provide protection from CDI in an in vivo 
hamster challenge model, inducing high levels of serum antibodies142,146. VLA84 
has also been shown to be safe and well tolerated in Phase I clinical trials142. A 
bivalent toxoid vaccine developed by de Bruyn et al. is also undergoing Phase II 
clinical trials after proving to be safe and well tolerated in Phase I clinical trials, 
eliciting a strong immune response in both healthy adult and elderly subjects144. 
Vaccines have great potential for CDI prevention, but are limited in terms of 
treating CDI due to the time required for the patient’s immune system to respond. 
This has prompted a number of investigations into monoclonal antibody therapy143. 
Monoclonal antibody therapies currently undergoing clinical and pre-clinical trials 
include a fully humanised monoclonal antibody cocktail against TcdA and TcdB. 
This demonstrated strong neutralizing activity both in vitro and in an in vivo 
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hamster challenge model143 A combination of two monoclonal antibodies 
actoxumab (TcdA specific) and bezlotoxumab (TcdB specific) are currently in 
Phase III clinical trials after reducing the rate of recurrence in Phase II clinical trials 
by 73% among CDI patients treated with standard therapy147. Once again the latter 
is associated with disease prevention rather than treatment. Another antibody 
approach is hyperimmune bovine colostrum (HBC). Colostrum is the first milk 
collected from a lactating mammal after parturition and is rich in IgG. When a 
gestating dairy cow is repeatedly immunised with recombinant mutants of TcdA 
and TcdB, she will produce HBC with IgG against the toxins. HBC has shown 
promise as an effective therapy for CDI, but is still in the early stages of 
development148. 
1.5. Auranofin 
1.5.1. Background and overview of pharmacokinetics 
Auranofin [2,3,4,6-tetra-o-acetyl-1-β-D-glycotranosato-S-(triethyl-phosphine) gold] is a 
monomeric gold species with phosphine and thiol ligands in the linear 
arrangement149-152 shown in Figure 1.6 below153. Auranofin was introduced into 
clinical use in 1985 as an alternative treatment for rheumatoid arthritis to the 
injectable gold sodium thiomalate. However, the clinical side effects, poor 
pharmacokinetics, and concerns regarding the immune suppression that may be 
associated with long term use of auranofin saw a general preference to continue 
using gold sodium thiomalate154. As an already approved drug, repurposing 
auranofin has many benefits over novel drug discovery as it has already been 
proven safe for use in humans. This removes a significant portion of the time and 
cost constraints associated with drug discovery and development. 
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Figure 1.6: The chemical structure of auranofin. 
The gold-thiol complex (Au-S) of this compound is responsible 
for its reactivity with thiol-redox enzymes such as thioredoxin 
reductase.  
From http://www.jmfinechemicals.com/product/auranofin/ 
 
Only 15-25 % of an oral dose can be detected in the plasma154,155, most of which 
was absorbed via the gastrointestinal tract within 20 minutes of being 
administered156. In the plasma auranofin binds predominantly to albumin, reaching 
a peak concentration of 6-9ug/100ml within 1-2 hours. The plasma half-life is  
15-25 days with almost total body elimination after 55-80 days154,156. Auranofin is 
minimally retained in tissues with 85% of the administered dose excreted in the 
faeces and only 15% appearing in the urine150. Only 0.4% of the administered dose 
is concentrated in the kidneys157. This pharmacokinetic profile is ideal for treating 
CDI since the organism infects the distal colon and a large proportion of the 
administered dose will reach the site of infection. 
The most common side effect of treatment with auranofin is the development of 
soft and loose stools within the first few weeks of treatment. This may occur in up 
to 40% of patients, with 2-5% reporting watery diarrhoea150,154. It is suspected that 
this diarrhoea is caused by the effect auranofin has on sodium and water transport 
in the intestine. Diarrhoea associated with auranofin use can be alleviated by 
reducing the dose or stopping treatment, depending on severity, and will settle 
promptly once the drug is stopped. Sometimes dividing the dose or changing the 
timing will alleviate this problem155. Jackson-Rosario et al. were able to show that 
auranofin inhibited the growth of C. difficile in vitro at a concentration of 2 µM24. 
The standard dose of 3-6 mg auranofin for the treatment of rheumatoid arthritis is 
estimated to result in a concentration of 0.15 mM in the colon150,154. It is therefore 
reasonable that the required dose of auranofin for the treatment of CDI will be  
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10-fold lower than that needed for rheumatoid arthritis, and is unlikely to induce 
diarrhoea. 
Another side effect is a mild rash that occurs within the first year of treatment150,154. 
This rash is less common with auranofin treatment than it is with injectable gold 
compounds, where it can occur in up to 20% of patients, with 2-3% having to 
discontinue therapy due to a severe rash150. Other less common side effects include 
stomatitis, which affects 1-12% of patients, proteinuria which affects 5% of 
patients, conjunctivitis which affects 10% of patients, and thrombocytopenia and 
related bone marrow suppression, which are extremely rare. These less common 
side effects are associated with long-term auranofin treatment150,154. 
1.5.2. Mechanisms of action 
The main mechanism of action of auranofin is through inhibition of 
reduction/oxidation (redox) enzymes such as thioredoxin reductase (TrxR). The 
thiol ligand contained in auranofin has a high affinity for thiol and selenol groups, 
to which it forms a stable and irreversible adduct24,158. Redox enzymes such as 
TrxR are essential to many cellular processes; particularly in maintaining the 
intracellular levels of reactive oxygen species (ROS)158-161. Controlling the level of 
ROS to prevent the resulting DNA damage, is critical for the survival of all cell 
types, including cancer cells, parasites, and memory T cells that harbor pro-viral 
HIV DNA. These particular cell types all overexpress redox enzymes increasing 
the affinity of auranofin towards these cells158-161. Inhibition of redox enzymes 
alters the redox state of the cell which can lead to increased production of hydrogen 
peroxide and reactive oxygen species (ROS) that causes cellular oxidative stress 
and ultimately intrinsic apoptosis158-161. 
Auranofin has particularly potent activity for selenoproteins and selenium 
dependent enzymes because it also has a high affinity towards inorganic selenium 
in the form of selenide (HSe-). Auranofin and HSe- are able to form a stable adduct 
through displacement of the sulphur in the auranofin thiol with the Se in HSe-24, 
resulting in a hydrogen sulphide by-product and the auranofin selenium compound. 
Selenoproteins such as TrxR in mammalian cells, have been identified as a 
potential drug target for cancer158, while selenoproteins involved in Stickland 
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reactions in amino acid fermenting bacteria have been identified as a potential drug 
target for these bacterial infections24,162. 
1.5.3. Potential as a treatment for CDI 
Auranofin is being investigated as a treatment for a number of diseases including 
cancer, parasitic infections, bacterial infections, HIV and neurodegenerative 
disorders such as Parkinson’s disease and Alzheimer’s disease163. 
Auranofin shows potential as a narrow spectrum treatment for CDI as it targets the 
selenium dependent metabolic pathways used by C. difficile. Inhibiting these 
pathways also inhibits C. difficile growth, highlighting the dependence of this 
pathogen on these pathways24. Auranofin is able to block the primary metabolite 
selenium, rather than target individual metabolic pathways, which will limit the 
ability of the bacteria to acquire resistance to this therapy162. A computational 
analysis of bacterial genomes indicates that only 14% of bacteria utilise 
selenoproteins, so selenium targeted therapy can be considered narrow spectrum, 
minimising disruption to the intestinal microbiota and reducing the risk of 
recurrence24,162. Further to this, it has been shown that clostridia spp. that do not 
use selenoproteins, such as C. perfringens and C. tetani are not affected by 
auranofin. Clostridia belong to the phyla Firmicutes, one of the dominant phyla 
present in the intestinal microbiota24. No further work on auranofin as a treatment 
for CDI has been published, and there is no data available on the effects auranofin 
has on C. difficile sporulation and toxin production, or intestinal inflammation 
With increasing rates of treatment failure and recurrent CDI, there is a clear and 
urgent need for new therapies. There are many treatments currently being 
investigated including new antibiotics, FMT and immune therapies. These 
therapies have either shown little efficacy, are expensive, unpleasant and invasive, 
or are in the early stages of development and therefore will not be used in routine 
clinical therapy for some time. 
It is the aim of this study to assess the potential of auranofin as a treatment for CDI 
by continuing the work performed by Jackson-Rosario et al. The hypothesis for this 
study is that auranofin will prove to be an effective therapy for CDI that has a lower 
risk of recurrence than the current treatments due to a smaller impact on the host’s 
microbiota. 
INTRODUCTION 
 
35 
In order to achieve this main objective, assessing the validity of auranofin as a 
treatment for CDI, two aims have been devised. Aim 1 is to use in silico methods 
to identify potential selenoprotein genes in C. difficile 630 and confirm the 
conservation of these genes in a panel of clinical isolates. Aim 2 is to test the 
activity of auranofin on C. difficile using in vitro assays and then in an in vivo 
mouse model. 
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2. Methodology 
2.1. Identifying selenoproteins in the C. difficile using in silico 
methods 
The overall process used to identify selenoproteins in the C. difficile genome is 
outlined in Figure 2.1. For this in silico work, C. difficile 630 (NCBI164; accession 
number: NC_009089) was used as it is the model genome for C. difficile in silico 
work. The genome for C. difficile 630 was searched for selenocysteine insertion 
sequence (SECIS) elements using bSECISearch165 (Figure 2.1, process 1), an 
internet based program designed by Zhang and Gladyshev. This program identifies 
bacterial SECIS elements based on a bacterial SECIS consensus model. The key 
features of this consensus model, shown in Figure 2.2, are an apical loop of 3-14 
nucleotides (nt) with at least 1 conserved guanosine (G) among the first 2 nt, an 
upper stem of 4-16 base pairs (bp) and a spacing of 16-37 nt between the UGA 
codon and the apical loop165. The resulting sequences from bSECISearch were 
aligned to the annotated C. difficile 630 genome using a nucleotide BLAST166 
(NCBI, Blast+2.4.0; Figure 2.1, process 2) to identify the SECIS elements that were 
within the open reading frame of a gene. Any SECIS sequences that were not within 
an open reading frame were discarded. The gene sequences from BLAST were then 
put back through bSECISearch to confirm they contain a SECIS element (Figure 
2.1, process 3). Gene sequences that did not were discarded. The secondary 
structure of the remaining SECIS elements was determined using RNAfold167-169 
(Vienna RNA Webserver) and compared to the consensus SECIS element 
secondary structure determined by Zhang and Gladyshev (Figure 2.1, process 4). 
Those that did not conform to the consensus structure were discarded. The final list 
of potential selenoproteins were aligned with the genomes of 100 C. difficile strains 
in the Clostridium difficile txid1496 [ORGN] database (listed in Appendix 1) using 
nucleotide BLAST166 (Figure 2.1, process 5) to determine the level of conservation 
of these genes. 
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Figure 2.1: Flow diagram of the in silico method used to identify C. difficile 
selenoproteins. 
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Figure 2.2: Bacterial SECIS element consensus model. 
From Zhang and Gladyshev 2005. 
 
2.2. Investigating auranofin as a treatment for CDI using in vitro 
methods 
2.2.1. Routine in vitro methodology 
Bacterial culture methods 
All C. difficile isolates were stored in a glycerol stock at -80°C. When removed 
from storage, isolates were streaked for single colonies on brain heart infusion 
(BHI; Oxoid, Hampshire, England) agar with 0.1% (w/v) taurocholic acid sodium 
salt hydrate (Sigma-Aldrich, NSW, VIC) to allow for spore germination. All 
bacterial work including incubation periods were undertaken in a Don Whitley 
DG250 Workstation (Don Whitley Scientific, NSW, AUS), which maintained an 
anaerobic environment (10% H2, 10% CO2 in N2; BOC, NSW, AUS) at 37°C and 
75% humidity. For experiments using broth cultures, tryptone yeast extract (TY) 
broth containing 1% (w/v) tryptone (Oxoid), 0.5% (w/v) yeast extract (Oxoid), and 
1% (w/v) sodium chloride (NaCl, Biochemicals, NSW, AUS) in deionised water 
was used at it is a low nutrient media that supports toxin production and sporulation. 
All media was anaerobically conditioned prior to use by incubating in anaerobic 
conditions overnight. The strain used for growth assays and the animal model was 
C. difficile M7404. This strain belongs to the hypervirulent ribotype 027 and has 
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been responsible for outbreaks in Canada, UK and North America. The M7404 is 
a commonly used strain for controlled laboratory experiments. This strain was 
donated by Associate Professor Dena Lyras, Monash University, Clayton, Victoria.  
Tissue culture methods 
Routine culturing of Vero cells in Minimum essential media (MEM-alpha; Gibco, 
Life Technologies, NY, USA) containing 10% fetal bovine serum (FBS; HyClone, 
Thermo, Victoria, AUS), 100 units/ml penicillin-streptomycin (HyClone, Thermo) 
in T25 cell culture flasks (Nunc, Thermo) at 37℃ with 5% CO2 until 80% confluent 
and then passaged. 
Preparation of antibiotic stock solutions 
Auranofin (Enzo Life Sciences, United Biosciences, NSW, AUS) was prepared by 
dissolving 100 mg Auranofin in 100% ethanol (Chem-supply, Westlabs, VIC, 
AUS) to make a stock solution of 5895.36 µM. 
Metronidazole (Sigma-Aldrich) was prepared by dissolving 1.7 mg metronidazole 
in deionised water to make a stock solution of 1000 µM.  
Vancomycin (Sigma-Aldrich) was prepared by dissolving 10 mg of vancomycin 
hydrochloride in deionised water to make a stock solution of 3449.94 µM. Growth 
assays 
Further dilutions of these antibiotic stock solutions was done using deionised water 
as necessary. All concentrations in experiments take into account the volume of the 
media to which the antibiotic is added, and therefore refer to the final concentration 
of the antibiotic. 
2.2.2. Growth Assays 
Minimum inhibitory concentration 
To determine the minimum inhibitory concentration of auranofin, metronidazole 
and vancomycin required to inhibit C. difficile growth, a growth assay was set up 
in sterile 96 well, F-bottom cell culture plate (Cellstar, Greiner Bio-one, Interpath, 
VIC, AUS). The plates were prepared with titrations of auranofin serially diluted 
1:2 in anaerobically conditioned sterile TY, with a starting concentration of  
500 µM. The final column contained 0 µM. Controls were no treatment, which was 
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sterile TY, and the diluent for auranofin, ethanol, which was titrated 1:2 at a starting 
concentration of 2% (v/v), which was equivalent to the volume of auranofin added 
to the highest concentration of the treatment group. Each well was inoculated with 
100 µl of an overnight culture of C. difficile M7404 or an additional 100 µl of sterile 
TY for the no bacteria control. 
Plates were incubated anaerobically at 37℃ for 24 hours. Bacterial was growth 
tracked by measuring optical density (OD600nm) every 2 hours from inoculation 
for 10 hours and again at 24 hours using an Epoch 2 microplate reader (Biotek, 
Millennium Biosciences, VIC, AUS). 
MIC was defined as the minimum concentration where there was statistically less 
bacterial density than the control cultures. This represents inhibition of bacterial 
growth. Statistical analysis was performed using a 2-tailed unpaired t-test with 95% 
confidence interval. 
These assays were based on the broth diluton method for antimicrobial testing 
described by Weigand et al.170 
Auranofin growth assay 
A number of growth assays were performed to assess the ability of auranofin to 
inhibit C. difficile bacterial growth. These were based on experiments described by 
May et al., Merrigan et al. and Vohra et al.171-173 An overview of the method is 
provided in Figure 2.3. Concentrations tested include 0.1 µM (subinhibitory), 6 µM 
(Minimum inhibitory concentration; MIC), 50 µM, 200 µM and 500 µM. The last 
three concentrations are an equivalent to those used in the preliminary in vivo 
animal model. Controls in these assays include no treatment and the diluent ethanol, 
used at an equivalent volume to the auranofin treatment group in the respective 
assay. 
For each assay, 40 ml of TY broth (n=3) were inoculated with 1% (v/v) overnight 
culture of C. difficile M7404 and incubated anaerobically at 37℃ in an anaerobic 
chamber. Treatments were applied at 12 hours, which is the end of exponential 
growth. This time point is when the bacteria would be releasing toxins, which 
would be consistent with the treatment of disease in a clinical setting. OD600nm 
was measured at 0, 2, 4, 6, 8, 10, 12, 14, 16, 24 and 48 hours using an Epoch 2 
microplate reader as a measure of bacterial growth. Samples were taken at 0, 12, 
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24 and 48 hours for viable cell counts (VCC) and viable spore counts (VSC). 
Additional samples were taken at 48 hours and filtered using a 0.22 µm Millex-GP 
filter unit (Merck, VIC, AUS) for cell cytotoxicity assays (CCA). 
Statistical analysis of the growth assays and cell viability was performed using a  
2-tailed unpaired t-test with 95% confidence interval. 
 
 
Figure 2.3: Overview of the in vitro growth assay used to investigate auranofin as a treatment 
for CDI. 
 
Auranofin vs metronidazole vs vancomycin 
To compare the activity of auranofin against C. difficile with that of vancomycin 
and metronidazole MIC assays and growth assays were performed. The MIC assays 
were carried out as described above (2.2.2) with the addition of metronidazole and 
vancomycin plates. Each treatment had its own positive and negative controls on 
its sterile 96 well, F-bottom cell culture plate to eliminate excess variance from 
being across multiple plates. 
Growth assays were similar to those described above (2.2.2) with the addition of a 
set of groups that were treated at inoculation (0 hours) as well as the previously 
described 12 hour treatment groups. As described above, OD600nm was measured at 
0, 2, 4, 6, 8, 10, 12, 14, 16, 24 and 48 hours, VCC and VSC samples taken at 0, 12, 
24 and 48 hours. 
 Statistical analysis of the growth assays and cell viability was performed using a 
2-tailed unpaired t-test with 95% confidence interval. 
Viable cell counts (VCC) 
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Cell viability was assessed by VCC performed from samples taken at 0, 12, 24 and 
48 hours from the growth assay described above. Samples taken at each of these 
time points were serially diluted and 100 µl of each dilution from neat to 10-5 were 
inoculated onto BHI agar and incubated for 48 hours. Colonies on each plate were 
then counted and the average colony forming unit (CFU) was calculated using 
Equation 2.1. These assays were based on experiments described by May et al., 
Merrigan et al. and Vohra et al.171-173 
 
Equation 2.1: Average colony forming unit (CFU) 
𝐶𝐹𝑈 =
𝐴𝑣 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑖𝑛𝑜𝑐𝑢𝑙𝑢𝑚
 
 
Viable spore counts (VSC) 
Viability of the C. difficile spores was assessed by viable spore counts (VSC) 
performed from samples taken at 0, 12, 24 and 48 hours from the growth assay 
described above. Samples taken at each of these time points were heat killed at 
75℃ for 30 minutes to kill all vegetative cells. Samples were then serially diluted 
and 100 µl of each dilution from neat to 10-5 were inoculated onto BHI agar with 
0.1% (w/v) taurocholic acid sodium salt hydrate to germinate the spores. Plates 
were incubated for 48 hours and CFU was calculated as described above using 
Equation 2.1. Control plates for vegetative cells were also done by spreading the 
neat heat killed samples onto BHI agar without the germinant. As there was no 
germinant in this media, any colonies that grow on these plates likely grew from a 
vegetative cell. These assays were based on experiments described by May et al., 
Merrigan et al. and Vohra et al.171-173 
Cell cytotoxicity assay (CCA) 
Cytotoxic activity of the toxins was assessed using CCA, where the cytotoxic 
activity of Toxin B is tested with Vero cells. An overview of the method is provided 
in Figure 2.4. Samples taken from the growth assays at 48 hours were sterile filtered 
using a 0.22 µm Millex-GP filter unit and stored at 4°C. Vero cells at approximate 
80% confluency were passaged into 2 sterile 96 well, F-bottom cell culture plates 
at a concentration of 0.1x106 cells/ml and incubated at 37℃ with 5% CO2 until 
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80% confluent. Culture media was removed and the cells were washed with sterile 
1X Phosphate buffered saline [PBS; 0.52% (w/v) sodium phosphate monobasic 
(NaH2PO4; Biochemicals), 2.3% (w/v) sodium phosphate dibasic (Na2HPO4; 
Biochemicals), and 8.76% NaCl) and 150 µl of sterile MEM was added to each 
well. Filtered C. difficile samples were added to the wells as follows: wells 1 and 
24 of each row were designated non-stimulated (NS) and contained Vero cells in 
MEM alone, well 2 received 150 µl of filtered C. difficile or media control to make 
a 1:2 dilution of the original sample which was then serially diluted across wells 3 
to 23. The negative control was sterile MEM. An additional set of control samples 
from the growth assays (C. difficile + no treatment) was set up as described and 
treated with 0.1 µM and 50 µM of auranofin to directly test the effects of auranofin 
on the cytotoxic activity of Toxin B. The C. difficile toxin treated Vero cells were 
incubated for 20 hours at 37℃ with 5% CO2, after which the cells were observed 
for the lowest titration where all Vero cells were toxin affected (represented by the 
yellow circles in Figure 2.4). This titration is the cytotoxic end-point titre. These 
assays were based on the methods described by Just and Gerhard, Lyras et al. 
Merrigan et al. and Vohra et al.25,61,172,173 
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Figure 2.4: Overview of cell cytotoxicity assay (CCA). 
Used to test the level of cytotoxic activity of C. difficile TcdB against Vero cells. Yellow circles 
represent the lowest titration with no viable Vero cells remaining. 
 
2.3. Preliminary testing of auranofin as a treatment for CDI 
using an in vivo animal model 
2.3.1. CDI prophylaxis animal model 
To assess the potential of auranofin as a treatment for CDI, it was trialled in an  
in vivo murine model of CDI as a prophylaxis. This work was done with the 
assistance of Associate Professor Dena Lyras and her research group at Monash 
University, VIC, Australia. This model is described by Lyon et al. and  
Carter et al.174,175 All animal handling and experimentation were performed in 
accordance with institutional guidelines (Monash University AEC no. 
MARP/2014/142). 
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The in vivo model is outlined in Figure 2.5 below and the treatment and control 
groups are defined in Table 2.1. Male C57BL/6J mice (Walter and Eliza Hall 
Institute of Medical Research, VIC, AUS) at 6-7 weeks old were pre-treated with 
an antibiotic cocktail in their drinking water for 7 days to induce intestinal 
dysbiosis, making them susceptible to infection from C. difficile spores. The 
antibiotic cocktail contained 0.4 mg/ml kanamycin (Amresco, Astral Scientific, 
NSW, AUS), 0.035 mg/ml gentamicin (Sigma-Aldrich), 850 U/ml colistin (Sigma-
Aldrich), 0.215 mg/ml metronidazole, 0.045 mg/ml vancomycin, and 0.3 mg/ml 
cefaclor (Sigma-Aldrich).This was then followed by 2 days on cefaclor alone. 
Auranofin prophylaxis was started one day before infection at the doses of  
400 µg/ml (maximum dose able to be given due to the solubility of auranofin),  
200 µg/ml (1:2 maximum dose), and 40 µg/ml (1:10 maximum dose). Auranofin 
was given in the drinking water. Mice were infected with C. difficile by oral gavage 
of 106 C. difficile M7404 spores, and were monitored twice daily for signs of 
disease including weight loss, behavioural and physical changes, and diarrhoea. On 
the day of infection antibiotic pre-treatments were stopped and mice were given 
either the auranofin drinking water or plain drinking water. 
Mice were humanely killed by CO2 asphyxiation when the following endpoints 
were met: acute weight loss of greater than 10% body weight within any 24 hour 
period, chronic weight loss of greater than 15% body weight following infection, 
animals becoming moribund or showing any signs of irregular or laboured 
breathing, animals reaching a clinical severity score of 2 on activity, alertness, coat, 
eyes, diarrhoea, nose, dehydration, movement or food consumption. 
Faeces were collected at 24 hours post infection to enumerate C. difficile spore load 
by sporulation count. Faecal pellets were resuspended in sterile PBS (100 mg/ml), 
heat shocked for 30 minutes at 65℃ and plated on heart infusion (HI; Oxoid, 
Hampshire, England) agar containing 1.5% glucose (Merck), 0.1% (w/v) sodium 
taurocholate (New Zealand Pharmaceuticals, Palmerston North, NZ), 0.1% (w/v) 
L-cysteine (Sigma-Aldrich), 250 µg/ml D-cycloserine (Sigma-Aldrich), 8 µg/ml 
cefoxitin (Fluka, NSW AUS), 10 µg/ml erythromycin (Amresco), 12 µg.ml 
norfloxacin (Sigma-Aldrich, NSW, AUS), and 32 µg/ml moxalactam (Sigma-
Aldrich). Plates for sporulation count were incubated and CFU was calculated as 
previously described (2.2.2). 
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Figure 2.5: Overview of Monash CDI prophylaxis mouse model. 
 
Table 2.1: Treatment groups for in vivo trial of auranofin as CDI 
treatment. 
Treatment group Infected Uninfected 
Auranofin 400 µg/ml n=5 n=5 
Auranofin 200 µg/ml n=5 n=5 
Auranofin 40 µg/ml n=5 n=5 
Control (no treatment) n=5 - 
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3. Identifying selenoproteins in C. difficile using in silico 
methods. 
3.1. Background 
Selenium is an essential micronutrient for many organisms176. The primary role of 
selenium in a biological system is as a metal cofactor in a number of proteins known 
as selenoproteins162,177,178. Selenoproteins are found in all domains of life and 
primarily function as oxidoreductases179,180, using the selenium containing amino 
acid selenocysteine at the active site.  
Estimates on the proportion of bacteria that utilise selenium range from 14%24 to 
33.7%181. Currently there are only four selenoproteins identified in C. difficile; 
selenide water dikinase (SelD), the glycine reductase proteins GrdA and GrdB and 
the D-proline reductase protein PrdA. SelD is a part of the sel operon, the protein 
products of which play a role in selenocysteine synthesis and incorporation. 
Glycine reductase and D-proline reductase reduce the amino acids glycine and  
D-proline respectively through Stickland reactions for energy. It is not known how 
many other selenoproteins C. difficile may utilise. It is the aim of this work to 
identify potential C. difficile selenoproteins. 
Selenocysteine differs from cysteine by having a selenol (SeH) group instead of a 
thiol (SH) group182, which is more acidic. This makes selenocysteine ionized at a 
physiological pH (7.6), giving it increased catalytic activity compared to cysteine. 
Selenocysteine is an unusual amino acid in that it is encoded by an in-frame UGA 
or stop codon. Insertion of selenocysteine requires specialised proteins and 
insertion machinery. In prokaryotes, there are four proteins required for 
selenocysteine incorporation along with an mRNA stem-loop structure called the 
selenocysteine insertion sequence (SECIS). These proteins are selenocysteine 
synthase (SelA), selenocysteine-specific elongation factor (SelB), selenocysteine 
specific tRNASec (SelC) and SelD183-189. The genes for these proteins are located 
on the sel operon185-190, shown in Figure 3.1 below. 
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Figure 3.1: The sel operon. 
The genes and gene products are shown by the arrows with selD (selenide water dikinase), selA 
(selenocysteine synthase), selB (selenocysteine-specific elongation factor) and selC 
(selenocysteine-specific tRNA). Adapted from Gursinsky et al., 2000. 
 
Selenocysteine is synthesised from selenophosphate, which is synthesised in a 
multistep reaction catalysed by SelD, shown in Figure 3.2191. In this reaction 
hydrogen selenide is reduced to selenium and then bound directly to phosphate, 
with adenosine triphosphate (ATP) as the phosphate donor176,182-184,186,192,193. 
Selenophosphate then acts as the selenium donor in a reaction with SelC that is 
catalysed by SelA183,184, shown in Figure 3.3. SelC is a specialised tRNASec with 
the anticodon UCA that recognises the in-frame UGA codon for 
selenocysteine183,184,187-189,194. Initially charged with a serine176,182,183,185,192,195, it is 
pre-translationally converted to a selenocysteine by SelA176,183,184,192, which 
changes the hydroxyl group of the serine to a selenol group176,187-189,195,196. SelA 
utilises selenophosphate as the selenium donor176,182,186,193. 
 
 
Figure 3.2: Selenophosphate synthesis. 
SelD catalyses the synthesis of selenophosphate in a multistep reaction that utilises 
hydrogen selenide (HSe-) as the selenium donor and ATP as the phosphate donor. 
Adapted from Veres et al., 1994. 
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Figure 3.3: Selenocysteine synthesis. 
SelA converts the serine charged SelC to a selenocysteine charged SelC by converting the hydroxyl 
group of serine to a selenol group (circled in red). This reaction uses selenophosphate as the 
selenium donor. Adapted from Forchhammer and Bock 1991; and Veres et al., 1994. 
 
Selenocysteine is cotranslationally incorporated at an in-frame UGA codon with 
the aid of the SECIS element176,182-184,187-189,195-197 as outlined in Figure 3.4. In 
prokaryotes, the SECIS is located immediately downstream of the UGA codon176 
and interacts with SelB to recruit the tRNASec to the ribosome176,182,185,197. The 
selenoprotein specific transcription regulator SelB has a similar function to the 
general transcription regulator elongation factor (EF)-Tu. There is high sequence 
similarity in the N-terminal of SelB and EF-TU, which binds GTP and tRNA. The 
C-terminal of SELB has a specialised 17kDa domain called domain IVb, which is 
responsible for binding to the SECIS element182,185,192,195,197. The simultaneous 
binding of SelB to tRNASec, GTP and the SECIS element forms the quaternary 
complex SelB:GTP:selenocysteyl-tRNASec:SECIS, which can then bind to the 
ribosome. Interaction of the tRNASec anticodon at the ribosomal A site triggers 
the GTPase activity of SelB, which releases the tRNASec to allow incorporation of 
selenocysteine into the polypeptide chain. Once tRNASec has been released, SelB 
dissociates from the SECIS element, allowing translation to continue197. 
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Figure 3.4: Incorporation of selenocysteine. 
a) Upon detection of the UGA codon by the ribosome, SelB forms a quaternary complex with 
tRNASec, GTP and the SECIS element.  
b) GTP hydrolysis releases tRNASec into the ribosome A site. 
c) SelB dissociates from the SECIS element. 
d) Selenocysteine (U) is incorporated into the polypeptide chain and translation continues. 
Adapted from Allmang and Krol, 2006; Gursinsky et al., 2008; and Zhang et al., 2008 Fourmy 
2002. 
 
The SECIS element is unique to selenoprotein mRNA, and thus makes a good 
target when searching for selenoproteins. As bacterial SECIS differ from 
eukaryotic and archaic SECIS, a specialised SECIS search program is necessary. 
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Zhang et al. have developed such a program called bSECISearch, which predicts 
bSECIS and the open reading frame of bacterial selenoproteins using the consensus 
structure outlined in the methods chapter (Figure 2.2)165. This program combined 
with nucleotide BLAST and RNAfold were used to identify potential 
selenoproteins in the C. difficile 630 genome. 
3.2. Results 
The initial bSECISearch identified 385 SECIS–like structures in the C. difficile 630 
genome. The first nucleotide BLAST reduced this number to 283 by eliminating 
bSECISearch hits that did not correspond to a gene. These 283 genes were put back 
through bSECISearch individually to confirm the presence of a SECIS element. 
The secondary structure of the SECIS elements were predicted using RNAfold, and 
these structures were compared to the consensus structure derived by Zhang et al. 
After this manual comparison, there were 94 strong candidates for selenoproteins, 
including SelD, GrdB and PrdA. 
One gene that did not match the SECIS consensus structure was glycine reductase 
A (grdA), which is known to be a selenoprotein193,198. The only difference between 
the SECIS element of grdA and that of the consensus structure was the length of 
the upper stem. The consensus structure stipulated an upper stem of 4-16 base pairs 
(bp)165,193,198 while grdA has an upper stem of just three base pairs. Based on the 
knowledge that GrdA is a selenoprotein165,199,200, a reassessment of genes with a 
shorter upper stem was done to identify an additional five genes as potential 
selenoproteins. This change in length is supported by a number of studies that used 
mutated oligonucleotides of the Escherichia. coli selenoprotein formate 
dehydrogenase (fdhF) to determine the key features of the mRNA stem loop 
necessary for SelB binding and subsequent selenocysteine insertion197,199,200. These 
studies determined that key components of the fdhF SECIS element were the 
guanosine (G) in the beginning of the apical loop and a bulged uridine (U) at +17 
in the upper stem just prior to the apical loop. Further experiments also 
demonstrated that there was room for variability on the position of U, with 
interaction with SelB still being observed in oligonucleotides with U at positions 
16 and 18 instead of 17. This U also didn’t need to be bulged if the upper stem was 
U rich with multiple U residues197,199,200. Figure 3.5 shows the proposed new 
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consensus structure with a 3-16 bp upper stem that is U rich. The other features of 
the consensus structure remain unchanged from the Zhang and Gladyshev model. 
All selenoproteins were reassessed for this new consensus structure, including 
those that fitted with the one previously proposed by Zhang and Gladyshev. There 
were 13 genes that were identified using the Zhang and Gladyshev model but 
rejected by the model proposed here due to a lack of U residues in the upper stem. 
 
 
Figure 3.5: Proposed new consensus structure for bacterial SECIS elements. 
The Sec-UGA codon is shown in bold and is underlined. This consensus model includes an apical 
loop of 3-14 nt and an upper stem of 3-16 bp, at least one guanosine (G) among the first two 
nucleotides of the apical loop, a U rich region in the upper stem before the apical loop and a spacing 
of 16-37 nt between the UGA codon and the apical loop. 
 
The 86 potential selenoproteins identified using the new SECIS consensus structure 
along with their putative functional class201, level of conservation and U richness 
in the upper stem are presented in Table 3.1 below. Level of conservation was 
determined by comparing the genes from the C. difficile 630 genome to 100 other 
C. difficile genomes representing a variety of different ribotypes using NCBI Blast. 
The list of genomes from NCBI is shown in Appendix 1. The putative function of 
the protein products was determined using the Cluster of Orthologous groups 
(COGs) protein database201. Overall 61 (70.93%) of selenoproteins were 100% 
conserved, with 6 (6.98%) and 8 (9.30%) being very highly or highly conserved, 
respectively. Moderate to high conservation was found in 3 (3.49%), moderate in 
2 (2.33%) and low to moderate also in 2 (2.33%), with just 4 (4.65%) of 
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selenoproteins showing low levels of conservation. The average U richness in the 
upper stem before the apical loop was 43.02% (range: 83.33% to 14.29%). 
Selenoproteins with SECIS elements that scored 0% in this criterion were rejected. 
The SECIS element structures for these potential selenoproteins are shown in 
Appendix 2, including the 13 rejected by the new consensus model. 
 
Table 3.1: C. difficile selenoproteins 
Selenoproteins from C. difficile 630 (NCBI) that match the new SECIS consensus structure. Putative 
functional class determined from COG database, level of conservation in 100 C. difficile genomes 
from NCBI database using NCBI Blast and uridine richness of upper stem as an indication of 
strength of SelB binding to SECIS element. 
Selenoprotein name Putative function class 
Level of 
conservation 
Uridine 
richness 
of upper 
stem 
30S ribosomal protein S1 (RpsA) 
Translation, ribosomal 
structure and biogenesis 
100% 50% 
4-aminobutyrate aminotransferase 
(GabT) 
Amino acid transport and 
metabolism 
100% 33.33% 
ABC-transporter ATP-binding protein 
(LolD) 
Signal transduction 
mechanisms 
100% 66% 
ABC-transporter sugar-family ATP-
binding protein (SalY) 
Signal transduction 
mechanisms 
100% 60% 
Chromosomal replication initiation 
protein 
Replication, 
recombination and repair 
100% 40% 
Acetolactate synthase large subunit 
(IlvB) 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
100% 50% 
Alpha-mannosidase 
Carbohydrate transport 
and metabolism 
100% 20% 
Aminotransferase 
Amino acid transport and 
metabolism 
100% 50% 
Asparagine synthetase (AsnB) 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
100% 40% 
Aspartate aminotransferase (AspB) 
Amino acid transport and 
metabolism 
100% 66.66% 
Diguanylate kinase signalling protein  Cell motility 100% 33.33% 
DinG family helicase (DinG) 
Replication, 
recombination and repair 
100% 28.57% 
DNA mismatch repair protein (MutL) 
Replication, 
recombination and repair 
100% 50% 
DNA primase (DnaG) 
Replication, 
recombination and repair 
100% 50% 
D-proline reductase (PrdA) 
Amino acid transport and 
metabolism 
100% 50% 
Electron transport complex protein 
(RnfC) 
Energy production and 
conversion 
100% 25% 
Glutaminase (GlsA) 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
100% 60% 
GTP-binding protein (LepA) Translation 100% 50% 
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HAD-superfamily hydrolase 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
100% 57.14% 
Minor head protein 
General function 
prediction only 
100% 40% 
Iron-sulfur binding protein 
Cell 
wall/membrane/envelope 
biogenesis 
100% 28.57% 
Isoleucine-tRNA ligase (IleS) 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
100% 20% 
K/Mg/Cd/Cu/Zn/Na/Ca/Na/H-
transporting P-type ATPase (ZntA) 
Inorganic ion transport 
and metabolism 
100% 33.33% 
Lipoprotein signal peptidase (LspA) 
Signal transduction 
mechanisms 
100% 30% 
LysR family transcriptional regulator 
(LysR) 
Transcription 100% 16.66% 
M24 family peptidase (PepP) 
Amino acid transport and 
metabolism 
100% 33.33% 
MATE family drug/sodium antiporter 
(NorM) 
Defence mechanisms 100% 66.66% 
Putative membrane protein 
General function 
prediction only 
100% 33.33% 
Methionine gamma-lyase (MdeA) 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
100% 83.33% 
Putative methyltransferase 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
100% 42.86% 
Multidrug family ABC transporter/ 
ATP-binding protein/permease (MdlB) 
Defence mechanisms 100% 50% 
NhaC family Na(+)/H(+) antiporter 
Inorganic ion transport 
and metabolism 
100% 80% 
Bifunctional nitrilase/nitrile hydratase 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
100% 40% 
Prolyl-tRNA ligase (ProS2) 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
100% 20% 
PTS system lactose/cellobiose-family 
IIC component (CelB) 
Carbohydrate transport 
and metabolism 
100% 28.51% 
PTS system, fructose/mannitol-family 
IIC component 
Carbohydrate transport 
and metabolism 
100% 40% 
Oligopeptide transporter (OPT) 
Amino acid transport and 
metabolism 
100% 25% 
Peptidase, M20D family (AgbB) 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
100% 33.33% 
Peptidase, S9 family (DAP2) 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
100% 50% 
Pyruvate phosphate dikinase, 
PEP/pyruvate-binding 
Carbohydrate transport 
and metabolism 
100% 40% 
Signalling protein 
Signal transduction 
mechanisms 
100% 50% 
Sodium:solute symporter 
Inorganic ion transport 
and metabolism 
100% 60% 
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Spore cortex-lytic hydrolase (SleB) 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
100% 66.66% 
Thioredoxin-disulfide reductase 
(TrxB1) 
Post-translational 
modification, protein 
turnover and chaperones 
100% 20% 
Thiosulfate sulfurtransferase (SseA) 
Inorganic ion transport 
and metabolism 
100% 71.43% 
Type II secretion system protein (PulF) 
Intracellular trafficking, 
secretion and vesicular 
transport 
100% 20% 
UDP-glycosyltransferase, MGT 
subfamily 
Carbohydrate transport 
and metabolism 
100% 44.44% 
UvrABC system protein A  
Replication, 
recombination and repair 
100% 71.43% 
Queuine tRNA-ribosyltransferase (Tgt) 
Replication, 
recombination and repair 
100% 57.14% 
Selenide water dikinase (SelD) 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
100% 50% 
Sodium/glutamate symporter (GltC) 
Amino acid transport and 
metabolism 
100% 60% 
Spore maturation protein B (SpmB) 
Cell 
wall/membrane/envelope 
biogenesis 
100% 40% 
Threonine synthase (ThrC) 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
100% 40% 
Transcription antiterminator, PTS 
operon regulator  
Transcription 100% 42.86% 
C4-dicarboxylate anaerobic carrier 
(YfcC) 
Inorganic ion transport 
and metabolism 
100% 83.33% 
Exonuclease ABC subunit A (UvrA) 
Replication, 
recombination and repair 
100% 37.50% 
Glycine reductase complex component 
A (GrdA) 
Amino acid transport and 
metabolism: Energy 
production and conversion 
100% 50% 
Multidrug family ABC transporter 
permease 
Defence mechanisms 100% 50% 
23s ribosomal RNA (23s-rRNA) 
Translation, ribosomal 
structure and biogenesis 
100% 25% 
Two-component sensor histidine kinase 
(OmpR) 
Signal transduction 
mechanisms 
100% 50% 
Two-component response regulator Transcription 100% 83.33% 
Argininosuccinate synthase 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
Very high 20% 
Site-specific recombinase 
Replication, 
recombination and repair 
Very high 25% 
ABC transporter permease 
Inorganic ion transport 
and metabolism 
Very high 28.57% 
Membrane protein 
General function 
prediction only 
Very high 60% 
Transcriptional regulator, Xylose 
repressor (XylR) 
Transcription Very high 33.33% 
Xylose kinase (XylB) 
Carbohydrate transport 
and metabolism 
Very high 41.66% 
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Glycine reductase complex component 
B subunit gamma 
Amino acid transport and 
metabolism; Energy 
production and conversion 
High 42.86% 
Phage tail fiber protein 
General function 
prediction only 
High 42.86% 
Amidohydrolase 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
High 25% 
Transcriptional regulator, TetR family 
(TetR_N) 
Transcription High 40% 
Putative phage DNA-binding protein* 
(YjcR) 
General function 
prediction only 
High 14.29% 
Replication initiation factor Tn916-
like, CTn7-Orf27 
Replication, 
recombination and repair 
High 66.66% 
Pyrroline-5-carboxylate reductase 
(ProC2) 
Amino acid transport and 
metabolism 
High 37.5% 
Conjugative transposon protein (TpcC) 
General function 
prediction only 
High 40% 
PTS system lichenan-specific IIC 
component (LicC) 
Carbohydrate transport 
and metabolism 
Moderate-
high 
50% 
ATPase 
Inorganic ion transport 
and metabolism 
Moderate-
high 
14.29% 
Cell surface protein Extracellular structures 
Moderate-
high 
36.36% 
Cobalt-specific ABC transporter 
permease (EcfT) 
Inorganic ion transport 
and metabolism 
Moderate 40% 
DNA/RNA helicase 
Replication, 
recombination and repair 
Moderate 60% 
Putative hydrolase 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
Moderate-
low 
25% 
Conjugative transposon protein (Spr) 
General function 
prediction only 
Moderate-
low 
16.66% 
Conjugative transposon protein 
General function 
prediction only 
Low 50% 
Cell wall hydrolase 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
Low 25% 
Cell division FtsK/SpoIIIE-family 
protein 
Cell cycle control, cell 
division, and chromosome 
partitioning 
Low 60% 
Membrane protein 
General function 
prediction only 
Low 16.66% 
 
Overall, the majority of the potential selenoproteins identified were involved in 
metabolic pathways. As shown in Figure 3.6, the largest putative functional class 
was secondary metabolite biosynthesis, transport and catabolism with 18 potential 
selenoproteins, 14 of which were 100% conserved. Other transport and metabolic 
functions were amino acid transport and metabolism (10 selenoproteins), 
carbohydrate transport and metabolism (seven selenoproteins), inorganic ion 
transport and metabolism (eight selenoproteins) and energy production and 
conversion (three selenoproteins). Most of the selenoproteins identified in each of 
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these COGs were 100% conserved. There were a number of genes that were 
involved in information storage and processing, the largest proportion of which 
were involved in replication recombination and repair. In this functional class, there 
were 10 selenoproteins identified and most of them were 100% conserved. 
Transcription had seven selenoproteins with conservation ranging from 100% to 
low, while translation, ribosomal structure and biogenesis only had three 
selenoproteins, but these were all 100% conserved. Putative functional classes 
involved in cellular processes and signalling had the least number of selenoproteins 
overall. The largest putative functional class in this group was signal transduction 
mechanisms with five selenoproteins, which were 100% conserved. The smallest 
COGs were cell cycle control, cell division and chromosome partitioning, and cell 
motility, each with just one selenoprotein. The selenoprotein in cell motility, 
diguanylate kinase signalling protein, was highly conserved, while the conservation 
of the Ftsk/SpoIIIE-family protein from cell cycle control, cell division and 
chromosome partitioning was low. There were nine selenoproteins that could have 
their general putative function predicted, but not their actual cellular role201. 
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Figure 3.6: Putative functional classes of C. difficile selenoproteins. 
The selenoproteins identified in this study are grouped according to the putative functional class of 
the protein. These putative functional classes are based on the Cluster of Orthologous Groups 
classification. The grouping for level of classification (legend) is based on the data in Table 3.1. 
 
3.3. Discussion 
A good therapeutic target is one that has a high likelihood of being present, and one 
that is essential for bacterial survival202. Auranofin is able to prevent C. difficile 
from utilizing selenium to make selenoproteins by forming a stable adduct with 
inorganic selenium, thereby limiting its bioavailability24. It is clear from the results 
that selenoproteins in C. difficile are highly conserved, with 61 having 100% 
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sequence identity in a panel of 100 C. difficile strains from NCBI, and a further 14 
having highly similar (≥ 95%) sequence identity. Further to this there is a wide 
range of selenoproteins with various functions including metabolism, information 
storage and processing, as well as cellular processes and signalling. The breakdown 
of the putative functional classes of selenoproteins showed that more than 50% of 
the selenoproteins identified were associated with metabolism and energy 
conservation, indicating a strong reliance on selenium for these processes. This 
finding is not surprising since many of the known selenoproteins are 
oxidoreductases involved in metabolic pathways181,195. 
Dembek et al. used transposon-directed insertion site sequence (TraDIS) to 
generate a library of C. difficile transposon mutants. This method allowed them to 
identify 404 genes essential for in vitro growth and 798 genes likely to impact spore 
production29. Of the genes identified as potential selenoproteins from this work 11 
belong to the set identified as essential for in vitro growth, including 30S ribosomal 
protein S1, DNA mismatch repair protein, three membrane protein, 
methyltransferase, amidohydrolase and two cell surface proteins. There were also 
a number of proteins that were not themselves essential for growth but do form a 
part of essential pathways including ribosomal, metabolic, aminoacyl-tRNA 
biosynthesis, DNA replication, RNA polymerase, protein export, glutamine and 
glutamate metabolism54. 
The genes essential for growth are also likely to impact spore production along with 
aminotransferase, electron transport-complex protein, lipoprotein signal peptidase, 
LysR family transcriptional regulator, Na+/H+ antiporter, putative polysaccharide 
deacetylase, putative sodium:solute symporter, ribonuclease R, selenide water 
dikinase, argininosuccinate synthase, ABC transporter permease, glycine reductase 
complex component B subunit gamma, putative phage-tail fiber protein, 
conjugative transposon proteins, putative hydrolase, cell wall hydrolase, glycine 
reductase complex component A and spore maturation protein B29. 
With 10 potential selenoproteins being essential for bacterial growth and even more 
being involved, selenium metabolism and selenoprotein synthesis should prove to 
be an effective target for the treatment of CDI. Targeting pathways that are essential 
for bacterial growth is likely to be an effective method for treating infections. Since 
these pathways are highly conserved this reduces the risk of C. difficile developing 
IDENTIFYING SELENOPROTEINS IN C. DIFFICILE USING IN SILICO METHODS 
 
60 
resistance to the therapy202. Targeting pathways involved in sporulation has the 
added advantage of possibly reducing C. difficile transmission. C. difficile is 
capable of producing highly resilient spores that are able to survive exposure to 
antibiotics such as vancomycin and metronidazole. This is a contributing factor to 
the increase in recurrent and refractory CDI. If auranofin is able to prevent  
C. difficile from producing selenoproteins, then this would reduce bacterial growth 
and sporulation, thus treating the infection and possibly reducing the risk of 
recurrence and transmission of disease10,74,104. 
Zhang and Gladyshev who described the consensus model used by bSECISearch 
and for the manual analysis described above, determined the consensus structure 
based on the analysis of the UGA flanking region of 100 selenoprotein mRNA 
sequence165. By using RNAfold to compare the secondary structures, they were 
able to identify the common features to construct this consensus model165. Most of 
the potential selenoproteins described above conformed to this consensus structure 
with one notable exception. Glycine reductase complex component A, often 
referred to as glycine reductase selenoprotein A, has been demonstrated to be a 
selenoprotein193,198. Sliwkowski et al. have been able to demonstrate that glycine 
reductase activity is lost in selenium-deficient cells, but is regained once selenium 
is available again198. They were also able to confirm incorporation of selenium into 
the protein experimentally by using radiolabeled selenium (75Se) and high 
performance liquid chromatography (HPLC)193. 
The upper stem of the C. difficile 630 grdA SECIS element was 3 bp in length, 
which is shorter than that of the 4-16 bp specified by the consensus structure165. 
With the knowledge that GrdA is a selenoprotein, it is reasonable to investigate the 
possibility that the consensus structure proposed by Zhang and Gladyshev may not 
apply to all bacterial selenoproteins. Indeed, Zhang and Gladyshev acknowledged 
that their SECIS was a loose model to allow greater tolerance for variation165, 
although clearly GrdA was overlooked in the development of this model. The 
Zhang and Gladyshev model is also lacking a bulged uridine (U) in the upper stem, 
a feature that is considered a key component in the well-studied E. coli SECIS 
elements165,197,199,200. This bulged U was omitted based on the observation that the 
SECIS elements of many bacterial organisms including Clostridium sticklandii, 
Clostridium purinolycticum and Eubacterium acidaminophilum had little in 
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common with the E.coli SECIS elements165. Studies looking at the key components 
of the E.coli selenoprotein fdhA SECIS element found that although the bulge at 
U17 is a key component of the SECIS element, it is not essential for SelB binding, 
there merely needs to be sufficient U in the upper stem before the apical 
loop197,199,200. While many of these studies concluded that the upper stem needed 
to be a minimum of 4-5 bp197,199,200, they did present mutated oligonucleotides with 
an upper stem of just 3 bp. These oligonucleotides were still capable of binding to 
SelB, and thus facilitate selenocysteine insertion. While the authors did not address 
the shorter upper stem, it is highly suggestive that an upper stem of 3 bp, like the 
one in the grdA SECIS element, would still be functional. Therefore, the new 
bacterial SECIS consensus model proposed here has a number of features in 
common with the Zhang and Gladyshev model, namely a distance between the 
UGA and apical loop of 16-37 nt, an apical loop of 3-14 nt and at least 1 of the first 
2 nucleotides in the apical loop being G165, with the addition of a U rich region in 
the upper stem before the apical loop and an upper stem length of 3-16 bp. 
One limitation of this work is that it is entirely in silico. Further work would need 
to be done to confirm that the above proteins are in fact selenoproteins. This could 
be done by generating a knock-out SelD mutant of C. difficile. SelD is not essential 
for in vitro growth29 however it is important for selenium metabolism and 
selenoprotein synthesis, as it is the catalyst for the synthesis of selenophosphate, 
the selenium donor for selenocysteine. Without active SelD it is likely that the 
expression of other selenoproteins will be reduced. An analysis of the mRNA 
transcripts could identify the proteins whose expression is altered as a result of 
disrupting the selenium metabolism. Additionally, it would be useful to investigate 
the application of the bacterial SECIS consensus model proposed here on a variety 
of known selenoproteins from different bacteria to confirm its validity. The reduced 
constraints on the length of the upper stem may also identify a number of new 
selenoproteins. A further future addition to this work would be to look for 
homologous genes in other clostridia, including cysteine containing homologues, 
as this would provide further supporting evidence. 
In conclusion, there are a large number of highly conserved selenoproteins in the 
C. difficile 630 genome, many of which play essential roles in bacterial growth and 
sporulation. This makes selenium metabolism a strong therapeutic target as there 
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is a reduced chance of C. difficile acquiring resistance or being intrinsically 
resistant to selenium targeted therapies, such as auranofin. 
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4. Investigation of auranofin as a treatment for C. difficile 
infection 
4.1. Background 
C. difficile utilises stickland reactions for energy conservation in which the amino 
acids proline and glycine are reduced. In stickland reactions one amino acid acts as 
the electron donor by undergoing oxidative deamination, while the other acts as the 
electron acceptor by undergoing reductive deamination185,187-189,196. In Clostridia, 
proline and glycine reductase are both electron acceptors, being reduced to 
aminovaleric acid and acetic acid plus ammonia, respectively187-189. 
Glycine reductase catalyses the reductive deamination of glycine to acetyl 
phosphate and ammonium178,181,193,196,198. The grd operon (Figure 4.1) contains the 
genes grdA, grdB, grdC, grdD and grdE185,196. This operon also contains a gene 
predicted to encode proline aminopeptidase (proP)196 as well as thioredoxin (trx) 
and thioredoxin reductase (trxR)194. The glycine reductase complex contains three 
subunits GrdA (grdA), GrdB (grdB and grdE) and GrdC (grdC and grdD). GrdA 
and GrdB are selenoproteins185,196,203. A selenocysteine functions as the redox 
centre for the catalytic activity of these proteins180,193,198. Selenium is essential for 
the activity of the glycine reductase complex18,185,196. 
 
 
Figure 4.1: The glycine reductase (grd) operon. 
Adapted from Bouillaut, Self and Sonenshein 2013, and Jackson et al. 2006. 
 
The glycine reductase pathway is outlined in Figure 4.2. Glycine binds to GrdB 
which forms a Schiff base intermediate via an essential carbonyl moiety195,204-206. 
GrdA then cleaves this Schiff base, breaking the carbon-nitrogen bond194,195,204-206. 
This transforms glycine to ammonia and a carboxymethyl selenoether bound to the 
ionized selenocysteine residue in GrdA194,195,204-206. GrdC cleaves the 
carboxymethyl group and reduces it to an acetyl group which it then phosphorylates 
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into acetyl phosphate195,205,206. The now oxidised GrdA is reduced by NADPH 
dependent thioredoxin to start a new cycle194,204-206. Meanwhile the acetyl 
phosphate is converted to ATP by acetate kinase in the presence of 
ADP186,192,194,206. 
 
 
Figure 4.2: The glycine reductase pathway. 
Glycine binds to the GrdB subunit and is reduced by the GrdA subunit. GrdC then phosphorylates 
it to create acetyl phosphate which is converted into ATP by acetyl kinase. The now oxidised GrdA 
needs to be reduced to regain activity. This is done by NADPH dependent thioredoxin/thioredoxin 
reductase system. 
 
Proline reductase reductively cleaves D-proline to 5-aminovalerate185,194,196,207. The 
prd operon (Figure 4.3) contains the genes prdA, prdB, prdC, prdD, prdE1, prdE2 
and prdF185,194. The product of prdA is a proprotein that is cleaved into two 
subunits, a 23-kDa subunit containing a pyruvoyl group and a 45-kDa subunit194. 
The product of prdB is a selenoprotein similar to GrdB. PrdB and GrdB are highly 
conserved around the selenocysteine moiety suggesting a similarity in function194. 
The product of prdF is a proline racemase which converts L-proline to D-proline, 
the substrate for proline reductase. This allows C. difficile to utilise both D-proline 
and L-proline185. 
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Figure 4.3: The proline reductase (prd) operon. 
Adapted from Bouillaut, Self and Sonenshein, 2013 and Jackson et al., 2006. 
 
The proline reductase pathway is outlined in Figure 4.4. D-proline binds to the 
pyruvoyl group on the PrdA 23-kDa subunit possibly forming a Schiff base 
intermediate similar to that seen in the glycine reductase pathway. The 
selenocysteine in PrdB cleaves the carbon-nitrogen bond of the proline ring 
forming an unknown intermediate compound bound to the selenocysteine of PrdB. 
The final product, 5-aminovalerate, is formed by hydrolysis activity194,207. The 
PrdB subunit is oxidised in this reaction and needs to be reduced to regain activity. 
The electron donor for this redox reaction is unknown194,207. The reduction of  
D-proline does not yield a molecule with a high group transfer potential like ATP 
from the glycine reductase pathway194,207. Based on experiments with  
C. sporogenes, it has been suggested that proline reduction is coupled to the 
formation of a pH gradient across the cytoplasmic membrane194. It is likely that this 
chemiostatic mechanism is a key energy-yielding pathway that is critical for 
anaerobic bacteria specialising in Stickland fermentation of amino acids185,194,207. 
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Figure 4.4: The proline reductase pathway 
Proline binds to the PrdA 23-kDa subunit and is reduced by the PrdB subunit to produce  
5-aminovalerate. It is thought that the energy-yielding mechanism in this reaction is the formation 
of a pH gradient across the cytoplasmic membrane. The electron donor used to reduce PrdB to its 
active state is currently unknown. Adapted from Kabisch 1999 
 
Auranofin is a monomeric gold complex containing a gold-thiol (Au-S) bond 
stabilised by a triethylphosphine group. It is a potent inhibitor of selenoproteins 
such as thioredoxin reductase in mammalian cells and parasites such as 
Trypanosoma brucei and Schistosoma mansoni24. 
As previously discussed (Chapter 3), selenoproteins contain selenium in the form 
of selenocysteine, which is synthesised from selenophosphate. The synthesis of 
selenophosphate occurs in a reaction catalysed by SelD, where reduced selenium 
in the form of hydrogen selenide (HSe-) is bound to phosphorus using ATP as the 
phosphate donor. Talbot et al. demonstrated that auranofin is capable of inhibiting 
selenoprotein synthesis, and attributed this to disruption of selenium metabolism208. 
Jackson-Rosario et al. investigated the mechanisms of the interaction between 
auranofin and selenium metabolism in C. difficile and E. coli, which is a model 
organism for prokaryotic selenoprotein synthesis. They were able to demonstrate 
that auranofin reacts with HSe- to form a stable adduct, and that the addition of 
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auranofin to C. difficile cultures prevented the uptake of 75Se and subsequent 
selenoprotein synthesis24. Based on this, Jackson-Rosario et al. then investigated 
the impact of auranofin on E. coli (MC4100) and a number of C. difficile strains. 
Auranofin reduced the growth of E. coli at concentrations as low as 25 µM, and 
they observed that this growth reduction was similar to that seen in selD 
knockouts24. Auranofin inhibited the growth of C. difficile with no observable 
growth at a concentration of 2 µM24. 
These experiments provide strong evidence supporting the theory that auranofin 
interacts with selenium to prevent selenium metabolism and selenoprotein 
synthesis in C. difficile. However, in these experiments, the C. difficile cultures 
were treated with auranofin at inoculation. C. difficile produces its virulence 
factors, TcdA and TcdB, at the end of exponential growth phase and during 
stationary growth phase21,62. As these toxins are responsible for the pathology of 
CDI122, it is necessary to test the activity of auranofin against an established  
C. difficile culture in stationary growth phase, since this reflects when the infection 
would be treated in a clinical setting. 
It was the aim of these experiments to investigate the potential of auranofin as a 
treatment for CDI. This was done by investigating the activity of auranofin against 
an established in vitro C. difficile culture, looking at bacterial growth, cell viability, 
sporulation and toxin production. It was hypothesised that auranofin would inhibit 
the growth of C. difficile without stimulating an increase in sporulation or toxin 
production. 
To further elucidate the potential of auranofin as a treatment for CDI, it is necessary 
to compare the activity of auranofin against C. difficile to that of the current 
treatments, vancomycin and metronidazole. This was also done in vitro focusing 
on bacterial growth, cell viability and sporulation. It was hypothesised that 
auranofin would be non-inferior to vancomycin and metronidazole. 
The final component of this study was a preliminary animal trial to determine if 
auranofin could prevent CDI and its symptoms, as well as determine an effective 
and safe dose for further animal trials. These trials were performed at Monash 
University, Clayton VIC, Australia, with the assistance of Associate Professor 
Dena Lyras and Dr. Melanie Hutton. It was hypothesised that auranofin would 
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reduce the level of colonisation and offer protection from the cytotoxic activity of 
C. difficile toxins TcdA and TcdB. 
4.2. Results 
4.2.1. Minimum inhibitory concentration (MIC) and subinhibitory 
concentration of auranofin 
The minimum inhibitory growth (MIC) assays showed a significant reduction in 
cell densiy compared to the treatment group when treated with 6.25 µM of 
auranofin after 2 hours (p=0.0008). This was consistent through all time points up 
to 24 hours. Auranofin at a concentration of 3.125 µM showed inconsistent 
inhibition of C. difficile M7404 growth, being significantly less than the untreated 
groups at some, but not all time points. This indicates that the MIC is between 3.125 
and 6.25 µM. For all further experiments, MIC is used to describe a concentration 
of 6 µM of auranofin. Auranofin at a concentration of 0.098 µM showed no 
inhibition of bacterial growth at any time point, and is therefore subinhibitory. For 
all further experiments, a subinhibitory concentration of auranofin refers to a 
concentration of 0.1 µM. Figures 4.5 to 4.11 show the bacterial growth with 
treatment concentrations ranging from 100 µM through to 0.098 µM of auranofin. 
 
Figure 4.5: Auranofin MIC assay, 100 µM auranofin. 
Mean absorbance for cultures treated with 100 µM auranofin or 2% ethanol. Controls are no 
treatment and sterile TY broth. n=3. Error bars show standard error of the mean (SEM). The p-
values are comparing auranofin to the no treatment control using a students t-test: 2 hours p=0.0005, 
4 hors p=0.0005, 6 hours p=0.0296, 8 hours p<0.0001, 10 hours p=0.0093 and 24 hours p=0.0001. 
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Figure 4.6: Auranofin MIC assay, 50 µM aurnaofin 
Mean absorbance for cultures treated with 50 µM auranofin or 1% ethanol. Controls are no treatment 
and sterile TY broth. n=3. Error bars show standard error of the mean (SEM). The p-values are 
comparing auranofin to the no treatment control using a students t-test: 2 hours p=0.0241, 4 hours 
p=0.0159, 6 hours p=0.0004, 8 hours p=0.0059 and 10 hours p=0.0035. 
 
Figure 4.7: Auranofin MIC assay, 25 µM auranofin. 
Mean absorbance for cultures treated with 25 µM auranofin or 0.5% ethanol. Controls are no 
treatment and sterile TY broth. n=3. Error bars show standard error of the mean (SEM). The p-
values are comparing auranofin to the no treatment control using a students t-test: 2 hours p=0.0023, 
4 hours p=0.0179, 6 hours p=0.001, 8 hours p=0.0155, 10 hours p=0.003 and 24 hours p=0.0009. 
INVESTIGATION OF AURANOFIN AS A TREATMENT FOR C. DIFFICILE INFECTION 
 
70 
 
Figure 4.8: Auranofin MIC assay, 12.5 µM aurnaofin 
Mean absorbance for cultures treated with 12.5 µM auranofin or 0.25% ethanol. Controls are no 
treatment and sterile TY broth. n=3. Error bars show standard error of the mean (SEM). The p-
values are comparing auranofin to the no treatment control using a students t-test: 2 hours p=0.0128, 
4 hours p=0.0006, 6 hours p=0.0074, 8 hours p=0.0023, 10 hours p=0.0072 and 24 hors p=0.0196. 
 
Figure 4.9: Auranofin MIC assay, 6.25 µM auranofin 
Mean absorbance for cultures treated with 6.25 µM auranofin or 0.125% ethanol. Controls are no 
treatment and sterile TY broth. n=3. Error bars show standard error of the mean (SEM). The p-
values are comparing auranofin to the no treatment control using a students t-test: 2 hours p=0.0008, 
4 hours p=0.0006, 6 hours p=0.0328, 8 hours p=0.0.0211, 10 hours p=0.0257 and 24 hours p=0.018. 
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Figure 4.6: Auranofin MIC assay, 3.125 µM auranofin 
Mean absorbance for cultures treated with 3.125 µM auranofin or 0.0625% ethanol. Controls are no 
treatment and sterile TY broth. n=3. Error bars show standard error of the mean (SEM). The p-
values are comparing auranofin to the no treatment control using a students t-test: 2 hours p=0.0319, 
6 hours p=0.0372 and 8 hours p=0.0063. 
 
Figure 4.7: Auranofin MIC assay, 0.098 µM auranofin. 
Mean absorbance for cultures treated with 0.098 µM auranofin or 0.002% ethanol. Controls are no 
treatment and sterile TY broth. n=3. Error bars show standard error of the mean (SEM). 
 
Growth assays observing the effect of the MIC and subinhibitory concentrations of 
auranofin on the growth of an established culture, as well as cell viability and 
sporulation, were performed. After treatment at 12 hours, all three treatment groups 
showed a decrease in cell density, with the effect of auranofin being greater in the 
subinhibitory group than the MIC group, although this was not significant. The 
subinhibitory group then plateaued to match the control group, while the ethanol 
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and MIC groups both continued to decrease in cell density, indicating inhibition of 
bacterial growth. The MIC group had significantly less bacterial growth than the 
0.1% ethanol group at 14 hours (p=0.0258) and 16 hours (p=0.0008), but at the 
later time points there was no difference between the two. The OD600nm of the four 
groups across all time points is shown in Figure 4.12. 
 
 
Figure 4.8: Bacterial growth of C. difficile M7404 treated with 0.1 µM auranofin, 6 µM 
auranofin, 0.1% ethanol (v/v) or no treatment (control). 
Mean absorbance for cultures. Dotted line represents the treatment time point, * indicates a p-value 
of <0.05, n=3. Error bars show SEM. 
 
The cell viability of C. difficile M7404 was greatly reduced by treatment with  
6 µM of auranofin and 0.1% ethanol, with the reduction of viability being greater 
in the auranofin group at 24 and 48 hours. The subinhibitory concentration of 
auranofin did not significantly reduce viability at 24 hours and there was only a 
slight decrease in cell viability at 48 hours. The cell viability for all groups at 0, 12, 
24 and 48 hours is shown in Figure 4.13. 
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Figure 4.9: Vegetative cell viability of C. difficile M7404. 
Treatment groups 0.1 µM auranofin, 6 µM auranofin, 0.1% ethanol and no treatment (control). 
n=3. Line represents mean CFU. Error bars show SEM. 
 
The sporulation of C. difficile M7404 was reduced in the MIC auranofin treated 
culture after 48 hours. There was little difference between any other treatment 
INVESTIGATION OF AURANOFIN AS A TREATMENT FOR C. DIFFICILE INFECTION 
 
74 
groups at 48 hours. At 0, 12, and 24 hours there was no difference between any of 
the treatment groups. The spore counts for all groups at 0, 12, 24 and 48 hours is 
shown in Figure 4.14. 
 
 
Figure 4.10: Spore counts for C. difficile M7404 cultures. 
Treatment groups 0.1 µM auranofin, 6 µM auranofin, 0.1% ethanol and no treatment (control). 
n=3. Line represents mean CFU. Error bars show SEM. 
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4.2.2. Treatment concentrations of auranofin 
Auranofin was then tested at the proposed treatment concentrations of 500 µM,  
250 µM and 50 µM. The highest concentration (500 µM) is equivalent to the 
maximum dose that can be given in an in vivo mouse model due to the solubility 
properties of auranofin. The middle treatment dose (250 µM) is half of the 
maximum dose and the lowest concentration (50 µM) showed a significant 
reduction in bacterial growth in the MIC assay above (4.2.1). 
Initially the lowest treatment dose was compared to an equivalent concentration of 
the diluent ethanol (0.8%). Due to the rate at which the bacteria grew, treatment 
was brought forward to 10 hours. Cell viability and sporulation assays were not 
performed. There was a significant reduction in the cell density of C. difficile 
M7404 treated with 50 µM auranofin at 12 hours compared to both the control 
group (p=0.0001) and ethanol (p=0.0093). This decrease in cell density was even 
more pronounced at 24 hours (p<0.0001, p=0.0004, respectively). There was no 
significant difference between the ethanol treated cultures and the control group at 
any time point. The bacterial growth of the three groups across all time points is 
shown in Figure 4.15. 
 
 
Figure 4.11: Bacterial growth of C. difficile M7404 treated with 50 µM auranofin, 0.8% 
ethanol (v/v) or no treatment (control). 
Mean absorbance for cultures. Dotted line represents treatment time point, *** indicates a p-value 
of <0.001, n=3. Error bars show SEM. 
 
Growth assays to test all three treatment cultures were then performed, looking at 
bacterial growth, cell viability, sporulation and toxin activity. All three auranofin 
treatment groups (50 µM, 250 µM and 500 µM) showed a significant reduction in 
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cell density at 24 hours compared to the control group (p<0.0001, p<0.0001 and 
p=0.0003, respectively). The bacterial growth of the four groups across all time 
points is shown in Figure 4.16. 
 
 
Figure 4.12: Bacterial growth of C. difficile M7404 treated with auranofin at concentrations 
of 50 µM, 250 µM and 500 µM compared to no treatment (control). 
Mean absorbance for cultures. Dotted line represents treatment time point, ***/+++/xxx indicates a 
p-value of <0.001, n=3. Error bars show SEM. 
 
The cell viability in all three treatment groups was significantly reduced compared 
to the control group (p=0.0017, p=0.0011 and p=0.0017, respectively). The cell 
viability for all groups at 0, 12, 24 and 48 hours is shown in Figure 4.17. The 
viability of the bacterial cells in the 50 µM and 250 µM group was significantly 
higher than that of the 500 µM and control groups. The reason for this is unclear as 
all groups contained the same media, were inoculated with the same overnight 
culture and were incubated under the same conditions at the same time. 
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Figure 4.13: Vegetative cell viability of C. difficile M7404. 
Treatment groups 50 µM auranofin, 250 µM auranofin, 500 µM auranofin and no treatment 
(control). */+/x indicates a p-value of <0.05, **/++/xx indicates a p-value of <0.01, n=3. Line 
represents mean CFU. Error bars show SEM. 
 
There was also a significant reduction in the number of viable spores in all three 
treatment groups (p=0.0313, p=0.0306 and p=0.0304, respectively). The spore 
count for all groups at 0, 12, 24 and 48 hours is shown in Figure 4.18. There was 
also a decrease in the number of viable spores in the control group between 24 and 
48 hours. This was unexpected, but is likely due to the highly variable nature of  
C. difficile, in particular C. difficile spores. 
0 hour 12 hour 
24 hour 48 hour 
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Figure 4.14: Spore counts for C. difficile M7404 cultures. 
Treatment groups 50 µM auranofin, 250 µM auranofin, 500 µM auranofin and no treatment 
(control). */+/x indicates a p-value of <0.05, **/++/xx indicates a p-value of <0.01, n=3. Line 
represents mean CFU. Error bars show SEM. 
 
Cell cytotoxicity assays (CCA) were performed on sterile filtered C. difficile 
M7404 culture supernatant from the 48 hour time point. All three treatment groups 
had a significant reduction on the level of cytotoxic activity observed against Vero 
cells, with both the 250 µM and 500 µM group being the same as non-stimulated 
Vero cells. The 50 µM group still showed some cytotoxic activity but this was 
significantly reduced compared to the control group (p=0.0406). The results of the 
0 hour 12 hour 
24 hour 
48 hour 
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cytotoxicity assay are shown in Figure 4.19. When the supernatant from the control 
C. difficile M7404 group was added to Vero cells with 50 µM of auranofin, there 
was a complete reduction in the cytotoxic activity observed against Vero cells 
treated with control C. difficile M7404 supernatant alone, as seen in Figure 4.20. 
 
 
Figure 4.19: Cytotoxic activity of C. difficile TcdB against Vero cells. 
Toxins in C. difficile M7404 supernatant treatment with 50 µM, 250 µM, 500 µM 
auranofin or no treatment (control). Toxin end-point titre represents lowest titration 
of C. difficile supernatant with 100% affected Vero cells. * indicates p-value of <0.05, 
n=3. Error bars show SEM. 
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Figure 4.15: Cytotoxic activity of C. difficile TcdB against 
Vero cells. 
Toxins in C. difficile M7404 control group supernatant were 
compared to this same supernatant with 50 µM of auranofin added 
when applied to Vero cells. Toxin end-point titre represents lowest 
titration of C. difficile supernatant with 100% affected Vero cells. 
n=3. Error bars show SEM. 
 
4.2.3. Comparison of the activity of auranofin with that of vancomycin 
and metronidazole 
The activity of auranofin against C. difficile M7404 was compared to that of 
vancomycin and metronidazole to confirm that auranofin was non-inferior to the 
current treatments for CDI. First an MIC assay was performed to determine the 
minimum inhibitory concentration of each antibiotic. Auranofin inhibited  
C. difficile M7404 growth at concentrations as low as 1.95 µM at 4 hours, but this 
was not observed at 8 and 24 hours. Inhibition at 3.91 µM and higher was 
consistently seen at 4, 8 and 24 hours. To retain consistency with the previous 
auranofin experiments, an MIC of 6 µM was used for the following experiments. 
The 0, 4, 8 and 24 hour time points for the auranofin MIC assays are shown in 
Figure 4.21. Vancomycin inhibited bacterial growth at 3.91 µM, however this was 
only seen at 24 hours. At 8 hours inhibition was seen as low as 7.81 µM. For the 
following in vitro experiments an MIC of 8 µM was used for vancomycin. The 0, 
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4, 8 and 24 hour time points for the vancomycin MIC assays are shown in Figure 
4.22. Metronidazole showed activity as low as 3.91 µM at 4 hours, but this was 
reduced to 7.81 µM at 8 hours and 15.63 µM at 24 hours. For the following in vitro 
experiments an MIC of 16 µM was used for metronidazole. The 0, 4, 8 and 24 hour 
time points for the metronidazole MIC assays are shown in Figure 4.23. 
 
 
Figure 4.16: Auranofin MIC titration assay for C. difficile M7404. 
Mean absorbance for cultures. Auranofin compared to no treatment (control). n=4. Error bars show 
SEM. 
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Figure 4.17: Vancomycin MIC titration assay for C. difficile M7404. 
Mean absorbance for cultures. Vancomycin compared to no treatment (control). n=4. Error bars 
show SEM. 
 
Figure 4.18: Metronidazole MIC titration assay for C. difficile M7404. 
Mean absorbance for cultures. Metronidazole compared to no treatment (control). n=4. Error bars 
show SEM. 
 
Next, growth assays to test and compare the effect auranofin, vancomycin and 
metronidazole had on C. difficile M7404 were performed, looking at bacterial 
growth, cell viability and sporulation. In these assays three sets of cultures (n=3) 
were treated with either auranofin, vancomycin or metronidazole at inoculation. 
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Another three sets of cultures (n=3) were treated at 12 hours to represent an 
established infection. Additionally, there was an untreated control group. 
All groups treated with auranofin, vancomycin or metronidazole at inoculation 
showed no bacterial growth. Auranofin and vancomycin cultures treated at 12 hours 
both had significantly reduced growth compared to the control groups at 36 hours 
(p<0.001), 48 hours (p<0.0001) and 60 hours (p<0.0001). There was no significant 
difference between the auranofin and vancomycin treated cultures. Cultures treated 
with metronidazole at 12 hours initially showed a reduction in growth at 36 hours 
(p<0.001), but subsequently there was increased growth higher than that of the 
control group (p<0.0001). The bacterial growth of the four groups across all time 
points is shown in Figure 4.24. 
 
Figure 4.19: Bacterial growth of C. difficile M7404 
Mean absorbance for cultures. Treated with 6 µM auranofin, 8 µM vancomycin, 16 µM 
metronidazole or no treatment (control). ***/+++/xxx indicates a p-value of <0.001, n=9. 
Error bars show SEM. (a) Groups that were treated at inoculation (0 hour). (b) Groups treated 
at 12 hours (stationary phase) 
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The cell viability of the C. difficile groups treated at inoculation with auranofin, 
vancomycin and metronidazole decreased immediately and there were no viable 
cells at 12 hours. The cell viability of the auranofin and metronidazole 12 hour 
treated groups were reduced compared to the control group at 24 hours. At 48 hours 
the cell viability of the metronidazole group had increased to greater than the 
control group. At 48 hours there were no viable cells in the auranofin treated 
groups. The vancomycin 12 hour treated group had a higher number of viable cells 
than the control group at 24 hours. This group had decreased 10 fold by 48 hours, 
although this was still higher than the auranofin. The cell viability for all groups at 
0, 12, 24 and 48 hours is shown in Figure 4.25. 
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Figure 4.20: Vegetative cell viability of C. difficile M7404. 
Treated with 6µM auranofin, 8 µM vancomycin or 16 µM metronidazole at either inoculation 
(0 hours) or beginning of stationary phase (12 hours), compared to no treatment (control). 
n=9. Line represents mean CFU. Error bars show SEM. 
 
All treatment groups had no spores at 24 hours, while the control group had begun 
to sporulate. The metronidazole 12 hour treated group began to sporulate between 
24 and 48 hours, although the number of viable spores was not as high as the control 
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group. All other treatment groups still had no spores at 48 hours. The spore viability 
for all groups at 0, 12, 24 and 48 hours is shown in Figures 5.26. 
 
 
Figure 4.21: Spore count of C. difficile M7404 cultures. 
Treated with 6 µM auranofin, 8 µM vancomycin or 16 µM metronidazole at either 
inoculation (0 hours) or beginning of stationary phase (12 hours), compared to no 
treatment (control). n=9. Line represents mean CFU. Error bars show SEM. 
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4.2.4. Preliminary testing of auranofin as a treatment for CDI using 
an in vivo animal model 
Preliminary animal trials were performed to investigate the potential of auranofin 
as a treatment for CDI in an in vivo model. The model used was the Monash CDI 
prophylaxis mouse model (see 2.3.1) which used 6 week old, male C57BL/6J mice. 
The intestinal microbiota of these mice was disrupted with an antibiotic cocktail 
given in their drinking water. Prophylaxis with auranofin given in their drinking 
water was commenced one day prior to infection with 106 C. difficile M7404 
spores, this was administered by oral gavage. Mice were monitored for signs of 
disease including weight loss, behavioural and physical changes, and diarrhoea. 
The mice that were infected and given no treatment had 0% survival after 2.5 days 
and the mice that were uninfected and treated with either 400 µg/ml, 200 µg/ml or 
40 µg/ml of auranofin had 100% survival at day 4. 
There was 25% survival in the infected mice treated with the lowest dose of 
auranofin after 2.5 days (Figure 4.27a), which is only slightly higher than the 
infected, no treatment control group. The rate of weight loss for this group was 
similar to the infected, no treatment control group, but didn’t begin until 0.5 days 
later (Figure 4.27b). This indicates that the lowest dose of 40 µg/ml auranofin was 
not enough to provide complete protection, but was sufficient to delay the onset of 
disease symptoms. There was no significant difference in the level of C. difficile 
colonisation after 48 hours (Figure 4.30) between the infected, 40 µg/ml auranofin 
mice and the infected no treatment control mice (p=0.09). The level of cytotoxic 
activity of TcdB against Vero cells was also similar for these two groups (Figure 
4.31). 
There was 100% survival in both the mice that were infected and treated with either 
200 µg/ml or 400 µg/ml of auranofin (Figures 4.28a and 4.29a respectively), 
indicating that both of these doses were able to protect the mice from CDI. 
Colonization with C. difficile after 48 hours was significantly lower than the 
infected, no treatment control (p=0.0206 and p=0.0257, respectively; Figure 4.30), 
which suggests that auranofin was able to reduce the bacterial load but not 
completely eradicate it. The mice treated with 400 µg/ml auranofin, both infected 
and uninfected, showed notable weight loss (Figure 4.29b). Although this weight 
loss was not enough to reach the experimental endpoint, it did indicate that this 
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dose is too high and the mice were experiencing adverse side effects from the 
auranofin. This weight loss was not observed in the mice treated with 200 µg/ml 
auranofin (Figure 4.28b), indicating that this dose is high enough to protect the 
mice from CDI, but not too high to cause adverse side effects. This was further 
supported by the lower level of cytotoxic activity of TcdB against Vero cells 
compared to the infected, untreated control group (Figure 4.31). 
 
 
Figure 4.22: Infected mice treated with 40 µg/ml auranofin. 
a) Survival of C. difficile infected mice treated with auranofin compared to uninfected mice 
and infected mice with no treatment. n=5 
b) Weight loss of C. difficile infected mice treated with auranofin compared to uninfected 
mice and infected mice with no treatment. Mean weight loss. n=5 
 
 
Figure 4.23 Infected mice treated with 200 µg/ml auranofin. 
a) Survival of C. difficile infected mice treated with auranofin compared to uninfected mice 
and infected mice with no treatment. n=5 
b) Weight loss of C. difficile infected mice treated with auranofin compared to uninfected 
mice and infected mice with no treatment. Mean weight loss n=5 
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Figure 4.29: Infected mice treated with 400 µg/ml auranofin. 
a) Survival of C. difficile infected mice treated with auranofin compared to uninfected mice 
and infected mice with no treatment. n=5 
b) Weight loss of C. difficile infected mice treated with auranofin compared to uninfected 
mice and infected mice with no treatment. Mean weight loss n=5 
 
 
Figure 4.24: Colonisation fo mice with C. difficile spores. 
Colonisation of mice infected with C. difficile spores after 48 
hours. Mice given no treatment or auranofin prophylaxis at  
40 µg/ml (1:100), 200 µg/ml (1:20) or 400 µg/ml (1:10). Line 
represents mean CFU, error bars are SEM. n=5 
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Figure 4.25: Cytotoxic activity of C. difficile TcdB. 
Cytotoxic activity of C. difficile toxin TcdB tested 
against Vero cells. Toxin was from faeces of mice 48 
hours after infection with C. difficile spores. Mice 
received no treatment or auranofin prophylaxis at  
40 µg/ml or 200 µg/ml. Error bars are SEM n=5  
 
4.3. Discussion 
C. difficile reduces the amino acids glycine and proline for energy production in a 
redox reaction catalysed by the selenoproteins glycine reductase and proline 
reductase. Synthesis of these proteins is a process that requires inorganic 
selenium24,185. It has been demonstrated that auranofin is capable of removing the 
bioavailability of selenium by forming a stable adduct with inorganic selenium 
through an irreversible reaction24. This prevents the synthesis of the selenoproteins 
that C. difficile requires for energy production, and thus inhibits the growth of  
C. difficile. The experiments by Jackson-Rosario et al. were the first step in 
investigating the potential of auranofin as a treatment for CDI. The work presented 
here takes the next step by demonstrating the bactericidal activity of auranofin 
against an established C. difficile culture, by showing non-inferiority of auranofin 
to the current treatments, vancomycin and metronidazole, and finally by 
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demonstrating that auranofin may be capable of preventing CDI in a prophylaxis 
mouse model. 
The in vitro model used in these experiments was developed to reflect an 
established infection. C. difficile produces the toxins TcdA and TcdB at the 
beginning of stationary growth phase21,62. Since these toxins are responsible for the 
pathology of the disease25, a patient infected with C. difficile is unlikely to be 
treated until after the bacteria has started producing toxins, since they will be 
asymptomatic up until this point. Once the toxins have started to be produced, the 
patient will show symptoms and seek medical treatment. It is at this point that a 
potential treatment for CDI needs to be tested to ensure that it is able to treat the 
infection rather than prevent it. Therefore the C. difficile cultures in these 
experiments were not treated until they had reached stationary growth phase. All 
in vitro growth assays were performed in a low nutrient media that promoted toxin 
production and sporulation. It should be noted that while stationary phase is the 
most clinically relevant cell stage, an infection is likely to contain different cell 
phases, including those in exponential growth phase. An assessment of activity 
against this phase is also necessary. In the Minimum Inhibitory Concentration 
(MIC) titration assays, cultures were treated at inoculation, as were the cultures in 
the experiments performed by Jackson-Rosarion et al24. Since an inhibition of 
bacterial growth was observed in these assays, it is reasonable to suggest that 
auranofin is active against C. difficile cells in exponential growth phase. 
MIC titration assays were used to establish the MIC for auranofin, vancomycin and 
metronidazole to be used in this model. The MIC for vancomycin and 
metronidazole determined in these assays was slightly higher than those reported 
by European Committee on Antimicrobial Susceptibility Testing (EUCAST)209. 
This is likely due to the difference in the method used to obtain these results. The 
EUCAST MIC distributions are determined using E-test agar diffusion209, however 
there is no standardised E-test available for auranofin. Since the auranofin MIC 
was determined by broth microdilution, the vancomycin and metronidazole MICs 
were determined by the same methods. 
The effect of auranofin at MIC on the growth of C. difficile was compared to that 
of ethanol, the diluent for auranofin. The reduction in cell density, indicating 
inhibition of bacterial growth, when treated with 6 µM auranofin was greater than 
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ethanol shortly after treatment, but by 48 hours the two showed the same reduction 
in bacterial growth. The difference in cell viability between the two at 24 and 48 
hours is significantly different, with the MIC of auranofin treated cultures having 
less viable vegetative C. difficile cells than the ethanol treated cultures. This 
indicated that OD, while suitable for cell density, should only be used as a guide 
for culture viability, because non-viable cells may contribute to the optical density 
of the solution. It is therefore necessary to assess the viability of the bacterial cells 
using additional methods. 
When the concentration of auranofin was increased to the lowest of the three 
treatment concentrations, the difference between auranofin and ethanol was clear. 
C. difficile cultures treated with auranofin at a concentration of 50 µM showed a 
rapid decrease in cell density, while the ethanol treated cultures initially showed a 
slight decrease, before continuing to grow at a rate similar to the control group. 
This indicated that the inhibited growth observed in auranofin treated C. difficile 
cultures is due to auranofin and not the diluent ethanol. 
All three treatment groups showed a significant reduction in bacterial growth after 
treatment with 50 µM, 250 µM or 500 µM of auranofin. There was also a decline 
in viable vegetative cells, with no viable cells remaining after 24 hours in the 
auranofin treated cultures. This indicates that auranofin appears to be bactericidal, 
capable of killing vegetative C. difficile, rather than bacteriostatic as was initially 
expected. The bactericidal activity of auranofin makes it a strong candidate as an 
alternative therapy for CDI. 
Auranofin at a concentration of 6 µM was compared to the MIC of the current CDI 
treatments vancomycin and metronidazole. Auranofin was shown to be non-
inferior to both of the current treatments causing an almost identical reduction in 
C. difficile cell density to treatment with vancomycin. Metronidazole also showed 
an initial decline in cell density until 36 hours, at which point these cultures showed 
an increase in bacterial growth until the OD was greater than the control groups at 
60 hours. This not only highlights the inferiority of metronidazole as a treatment 
for severe CDI when compared to vancomycin210 but also indicates that 
metronidazole may be inferior to auranofin. 
The viability of the vegetative cells treated with metronidazole and auranofin 
reflect the OD measurements. Metronidazole treated C. difficile cultures had a 
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reduction in the number of viable cells between 12 and 24 hours and an increase in 
the number of viable cells between 24 and 48 hours. At 48 hours, the number of 
viable cells in the metronidazole treated C. difficile cultures was greater than that 
in the control group. Auranofin treated C. difficile cultures showed a reduction in 
the number of viable cells between 12 and 24 hours and at 48 hours there were no 
viable cells remaining, thus providing further evidence that auranofin is 
bactericidal against C. difficile. The reduction in C. difficile viability when treated 
with vancomycin was delayed compared to the OD measurements and was less 
pronounced than the reduction observed in the auranofin treated C. difficile 
cultures, indicating vancomycin may be slower at killing the bacteria than 
auranofin. This is not surprising as vancomycin has been described as slow acting 
and bacteriostatic115. 
Overall these results indicate that the bactericidal auranofin is non-inferior to 
vancomycin as a treatment for CDI. These results also indicate that metronidazole 
may be inferior to auranofin and vancomycin as a treatment for CDI. Further 
investigations, including in vivo animal trials and human clinical trials, need to be 
performed to properly assess the effectiveness of auranofin as a treatment in 
comparison to vancomycin and metronidazole. 
C. difficile spores are the transmittable element10, so it is important to assess the 
impact of a treatment on sporulation and spore viability. Viable spore counts show 
that subinhibitory concentrations of auranofin do not influence sporulation, further 
supporting auranofin as a treatment for CDI, as diminished concentrations of 
auranofin in the gastrointestinal tract will not trigger or increase sporulation as is 
often the case with other treatments such as vancomycin109. An increase in 
sporulation would contribute to the spread of disease and increase the risk of 
recurrent infections10. Since auranofin does not increase sporulation, even at 
subinhibitory concentrations, this does not appear to be a problem associated with 
this potential treatment. In fact, MIC and treatment concentrations of auranofin 
reduced the number of viable spores from C. difficile cultures between 12 hours 
(treatment) and 24 hours, with a further reduction between 24 and 48 hours. The  
C. difficile cultures treated with 250 µM and 500 µM auranofin had no viable spores 
after 48 hours. 
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This reduction in spore counts strongly suggests that auranofin is in some way 
affecting the spores or the germination process. If auranofin were inhibiting the 
ability of the bacteria to produce spores, or the low spore counts were simply an 
artefact of the low number of viable cells, then there would be a plateau in the 
number of viable spores after treatment, rather than a decline. This narrows the 
possibility to affecting the viability of the spore itself, or affecting the germination 
process. Auranofin may be sporicidal or sporistatic. This is certainly an area that 
warrants further investigation, as a bactericidal treatment that is also sporicidal 
would prove to be very useful as a CDI treatment because it may also prevent 
recurrent infection and spread of disease. An unfortunate limitation of this work 
was the capacity of the anaerobic chamber limited the n for these experiments. This, 
coupled with the highly variable nature of C. difficile, did result in a loss of 
statistical power. However, as the difference between treated and untreated cultures 
was so large (greater than 100-fold in some instance) then these results still carry 
validity and should therefore not be discounted. Additional work using pure spore 
cultures and larger experimental numbers is required to fully elucidate the true 
effect of auranofin on C. difficile spores, but these results are certainly encouraging. 
The pathology of CDI is caused by the glycosylating toxins TcdA and TcdB25. To 
assess the impact of auranofin on the cytotoxic activity of TcdB and thus formulate 
a theory on how auranofin will affect disease pathology, cell cytotoxicity assays 
were performed using Vero cells, which lose their cellular structure when 
intoxicated with TcdB122. The cytotoxic activity observed from C. difficile cultures 
treated with 50 µM, 250 µM or 500 µM auranofin was significantly lower than that 
observed from the untreated C. difficile cultures. This finding was not surprising, 
as these cultures had a significant reduction in the number of viable cells, and hence 
less capacity to produce toxins. What was surprising was the finding that auranofin 
could directly alter the cytotoxic effect TcdB has on Vero cells. When Vero cells 
were given 50 µM of auranofin at the same time they were exposed to supernatant 
from control C. difficile cultures, the cytotoxic activity previously observed from 
this supernatant was completely reversed. Auranofin may be affecting the toxins 
directly or may affect the endosomal mediated uptake of the toxins by the Vero 
cells. Further work needs to be done to determine firstly if auranofin has a similar 
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effect on TcdA, and secondly if this is directly on the toxins or on the intoxication 
of the target eukaryotic cells. 
The preliminary in vivo work was performed using a CDI mouse model designed 
to replicate antibiotic associated CDI. In this model, the mouse intestinal 
microbiota is depleted with an antibiotic cocktail, and then the mice are infected 
with C. difficile spores. In this experiment, auranofin was given prophylactically 
one day prior to infection with C. difficile to determine if auranofin would have a 
strong enough effect on disease progression to warrant further investigation as a 
treatment. The three doses of auranofin used in this experiment, 40 µg/ml,  
200 µg/ml and 400 µg/ml, were chosen based on the maximum dose of auranofin 
able to be given to the mice (400 µg/ml), half the maximum dose (200 µg/ml) and 
one tenth the maximum dose (40 µg/ml). Controls for this experiment included the 
infected control and the uninfected control groups, and three additional uninfected 
mice groups, each receiving one of the three auranofin prophylaxis doses to observe 
any adverse effects caused by auranofin. 
The infected control group showed steady weight loss one day post-infection, 
which continued until the mice reach 15% loss of total body weight, at which point 
they are euthanized. This typically occurs two to three days post-infection. Mice 
surviving to four days post-infection are likely to recover from the disease. The 
survival and weight loss observations revealed that the low dose of 40 µg/ml is too 
low to prevent CDI, with 75% of the mice in this group reaching the weight loss 
endpoint of 15% total body weight. The uninfected mice receiving this dose did not 
display any weight loss, indicating that the weight loss in the infected group was 
associated with CDI rather than auranofin. 
The 400 µg/ml dose was able to prevent CDI, with 100% survival in this group. 
There was substantial weight loss in both the infected and uninfected mice 
receiving this dose, indicating that the weight loss observed here may be due to 
treatment with auranofin, rather than the infection. This dose may be therefore too 
high to be used for the treatment of CDI. 
The third dose, 200 µg/ml, demonstrated 100% survival without significant weight 
loss. It therefore appears to be the ideal dose for treatment of CDI as it is high 
enough to prevent CDI, and not cause apparent adverse side effects. This group had 
less C. difficile colonisation after 48 hours than the low dose and infected control. 
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This supports the theory that auranofin is preventing CDI, as well reducing the level 
of TcdB cytotoxic activity against Vero cells, which may be due to the low 
colonisation, or an indication that auranofin may also be capable of preventing the 
disease caused by the toxins. 
Further in vivo work is necessary to fully elucidate the role of auranofin as a 
treatment for CDI. This work will include full scale CDI mouse models testing 
auranofin as a prophylaxis and then as a treatment, as well as investigations using 
a recurrent CDI mouse model. Additionally, the mouse gut microbiota needs to be 
studied to determine the impact of auranofin since this is an indicator for recurrence 
of CDI32,33 
In conclusion, auranofin is able to reduce C. difficile cell viability in vitro at 
concentrations as low as 6 µM, as well as reduce the cytotoxic activity of the toxin 
TcdB at concentrations as low as 50 µM. Furthermore, auranofin does not increase 
sporulation, even at subinhibitory concentrations. Auranofin was non-inferior to 
vancomycin in vitro, and metronidazole was inferior to both auranofin and 
vancomycin in vitro. Preliminary in vivo mouse assays demonstrated that auranofin 
prophylaxis of 200 µg/ml daily can prevent antibiotic associated CDI in mice 
without adverse effects. 
The evidence presented here strongly supports investigating treatment of CDI with 
auranofin as an alternative to the current antibiotics, vancomycin and 
metronidazole. Further in vitro and in vivo studies are required, as discussed above, 
before validation in small scale human clinical trials. 
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5. Discussion and conclusion 
Clostridium difficile infection (CDI) is an antibiotic associated infection of the 
gastrointestinal tract. The current treatments, vancomycin and metronidazole, are 
associated with high levels of recurrent and refractory disease4,112,113. This is due 
to their disruption of the intestinal microbiota, which, when in extreme dysbiosis, 
requires a faecal microbiota transplant (FMT) to replenish the diversity of the 
microbiota32,33. It is clear that new therapies are needed to treat and prevent 
recurrent CDI, and while there are some new developments, many of these are 
expensive, such as fidaxomicin. 
One potential candidate, auranofin, was presented by Jackson-Rosario et al. 2009. 
This group investigated the growth inhibiting activity of auranofin on C. difficile, 
attributing this activity to the inhibition of selenoprotein synthesis in the bacteria24. 
There have been a number of studies, predominantly by Theresa Stadtman, that 
have identified selenoproteins utilised by C. difficile for amino acid fermentation, 
namely components of the glycine reductase and proline reductase 
pathways186,190,193,198,206,207. 
The aim of this study was to further investigate the repurposing of the arthritis drug 
auranofin, as a treatment for CDI. This overall aim was subdivided into two: the 
first was to investigate the number of potential selenoproteins in the C. difficile 
genome using in silico methods, and the second, to further investigate the growth 
inhibitory activity of auranofin on C. difficile using an in vitro model of CDI. 
The in silico investigation into the number of potential selenoproteins in C. difficile 
was necessary to assess the strength of selenium metabolism as a therapeutic target. 
This investigation identified 86 genes as potential selenoproteins in the C. difficile 
630 genome, 87.21% of which showed high levels of conservation (>95%) among 
100 C. difficile genomes. The protein products of these genes had a variety of 
putative functions including metabolism, information storage and processing, as 
well as cellular processes and signalling. 
The results of this investigation were surprising for a number of reasons. The first 
was the number of selenoproteins identified. Previously there were four confirmed 
selenoproteins found in C. difficile, (selenide water dikinase (SelD), glycine 
reductase complex protein A (GrdA), glycine reductase complex protein B (GrdB), 
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and D-proline reductase protein A (PrdA)211. The identification of a possible 82 
more was unexpected as there have not been any reports of a selenoproteomes of 
this size before. Previous reports on the number of selenoproteins in bacteria have 
identified a total of 25 different selenoproteins and three selenoprotein rich phyla: 
Deltaproteobacteria (22 selenoproteins), Firmicutes–Clostridia (16 selenoproteins) 
and Actinobacteria (12 selenoproteins)211. Further in vitro investigations are 
required to confirm that all the genes identified here produce functional 
selenoproteins. Even if just a portion of them are true selenoproteins, this would 
make the C. difficile selenoproteome the largest selenoproteomes ever reported. 
The second unexpected result was the high level of conservation among these 
genes. C. difficile has an unusually low level of genome conservation63,212, with 
reports estimating the core genome to be just 16-23% of the entire genome. This is 
one of the smallest core genomes of any bacteria212. A total of 61 of the 
selenoprotein genes identified here were 100% conserved and are therefore likely 
to play an essential role in C. difficile survival. This represents ~6.1% of the 
estimated C. difficile core genome. A further 14 were highly conserved. The sheer 
number of potential selenoproteins identified in C. difficile combined with the high 
levels of genome conservation and the variety of putative functions suggests that 
selenium plays an essential role in this organism. Based on these findings it can be 
concluded that selenium metabolism is a good therapeutic target to treat CDI. 
Once selenium metabolism was established as a good therapeutic target, it was 
necessary to test auranofin as a treatment for CDI in an in vitro model. This 
investigation found that auranofin was able to inhibit C. difficile growth and reduce 
cell viability at concentrations as low as 6 µM, eliminating all viable cells at a 
concentration of 50 µM. Auranofin also protected Vero cells from the cytotoxic 
activity of C. difficile toxins TcdA and TcdB, and did not increase sporulation. The 
activity of auranofin against C. difficile was more effective than initially 
hypothesized. It was originally thought that auranofin would be bacteriostatic and 
only inhibit bacterial growth, however the results strongly indicate bactericidal 
activity. There was clearly reduced cell viability at a concentration of 6 µM, and 
concentrations of 50 µM and higher consistently showed no viable bacterial cells 
after treatment. 
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Treatments such as Vancomycin can induce sporulation at subinhibitory 
concentrations109. Some disinfectants, such as alcohol based hand sanitizer, also 
promote sporulation4. C. difficile spores are highly resilient, able to survive in the 
environment for several months and are unaffected by antibiotics such as 
metronidazole and vancomycin. Spores are the transmissible element, so an 
increase in sporulation would contribute to the spread of CDI109. Spores also play 
a role in recurrent CDI94, with speculation that the recurrence of disease is caused 
by failure to eliminate the spores from the gastrointestinal tract. Upon cessation of 
antibiotic therapy, the spores would then be able to germinate, thus reviving the 
infection. An increase of sporulation would also increase the risk of recurrent 
disease. 
Auranofin did not induce sporulation, even at subinhibitory concentrations. After 
treatment with 6 µM or higher of auranofin, there was a reduction in the number of 
viable spores yielded, indicating that auranofin was in some way affecting the  
C. difficile spores. This activity could be sporicidal, affecting the viability of the 
spores, or sporistatic, affecting the germination process. Distinguishing between 
sporicidal and sporistatic activity is a somewhat difficult process, requiring the 
elimination of the active molecule, in this case auranofin. This may be either by 
physical removal of the molecule or by neutralizing its activity213. If auranofin were 
sporistatic, this may reduce the risk of recurrent CDI, as the remaining spores in 
the gastrointestinal tract would be unable to germinate, however it would be 
unlikely to reduce the spread of disease as the spores would be able to germinate 
inside a new host that has not been treated with auranofin. If auranofin were 
sporicidal, this could both reduce the risk of recurrence and spread of disease. 
Further work is required to fully elucidate the activity of auranofin against  
C. difficile spores. 
An unexpected outcome of this investigation was the elimination of C. difficile 
toxin activity by auranofin. It was not surprising that there was less toxin activity 
from the supernatant of C. difficile cultures treated with auranofin, as one would 
expect that these cultures would be producing less toxin, particularly since three of 
the known C. difficile selenoproteins play a role in energy production in this 
bacteria. However, auranofin was able to neutralize the activity of the toxins 
produced by the untreated control C. difficile cultures. These cultures normally 
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exhibit quite high cytotoxic activity against Vero cells, resulting in the Vero cells 
rounding and lifting from the surface of their well. The addition of 50 µM of 
auranofin at the time the C. difficile supernatant was added to the Vero cells media 
completely protected the Vero cells from the cytotoxic activity of the C. difficile 
toxins. It remains unclear if auranofin is directly affecting the toxin activity, or is 
in some way preventing the endosomal mediated uptake of the toxins51 by the Vero 
cells. While further work is needed to determine the mechanisms at work here, this 
finding is very significant given that the toxins are responsible for the pathology of 
CDI. The cytotoxic activity of the toxins TcdA and TcdB results in the apoptosis 
of the intestinal epithelial cells, which leads to the accumulation of fluid, 
inflammation and intestinal injury that are clinical symptoms of CDI52. Prevention 
of the apoptosis of the epithelial cells would lessen the severity of CDI in patients, 
reducing the likelihood of complications requiring surgical intervention and 
improve patient outcomes. 
The strong bactericidal activity and potential sporicidal activity of auranofin is 
most likely due to the essential nature of selenium that was highlighted in the results 
of the in silico component of this study. Selenium in the form of selenocysteine is 
known to be an essential component of the glycine reductase complex (GrdA, 
GrdB) and the proline reductase complex (PrdA)190,195,207. These proteins are 
responsible for the reduction of the amino acids glycine and proline, and form 
energy conservation pathways in C. difficile. By eliminating these energy 
conservation pathways through the removal of selenium, it was anticipated that 
bacterial growth would be affected. It is clear that auranofin causes more than just 
inhibition of C. difficile bacterial growth, indicating a stronger reliance on selenium 
than previously thought. Selenium utilization in C. difficile begins with the 
conversion of selenium to selenophosphate, the selenium donor for selenocysteine. 
The synthesis of selenophosphate is catalysed by the selenoprotein SelD29,181, 
which is known to be essential for selenium utilization in all domains of 
life29,181,211,214. It has been previously shown by Dembek et al. that SelD is essential 
for sporulation in C. difficile29, hence it was not surprising to discover that 
auranofin affected the viability and/or germination of C. difficile spores. However, 
Dembek et al. observed that SelD, was not essential for in vitro vegetative cell 
growth29, which was surprising given its essential role in selenium utilization. This 
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study identified a number of potential selenoproteins that are involved in the 
essential pathways for vegetative cell growth identified by Dembek et al., including 
ribosomal pathways, metabolic pathways, DNA replication pathways and 
secondary metabolite biosynthesis pathways29. While SelD may not be essential for 
C. difficile vegetative cell growth, selenium clearly plays a vital role in C. difficile 
growth, viability and sporulation. 
Based on the significant effects exhibited by auranofin on C. difficile in vitro, a 
preliminary in vivo investigation into auranofin as a treatment for CDI was 
performed at Monash University with the assistance of Associate Professor Dena 
Lyras and Dr Melanie Hutton. These experiments showed that a dose of 200 µg/ml 
was able to protect C57BL/6J mice from the cytotoxic effects of C. difficile. 
Limitations of this experiment were the small number of mice used (n=5) and the 
fact that auranofin was tested as a prophylaxis rather than a treatment. 
Unfortunately, due to time constraints further in vivo experiments were not 
performed, however there are plans for future experiments that will rectify the 
limitations discussed here. The results of this preliminary investigation are 
encouraging, and provide strong evidence supporting further testing of auranofin 
as a treatment for CDI. 
Auranofin effectively eliminated the viability, spread and cytotoxic effects of  
C. difficile by removing the bioavailability of selenium. As described by  
Jackson-Rosario et al., auranofin forms a stable and irreversible bond with 
inorganic selenium, thus preventing its use by the bacteria24. In their studies, 
Jackson-Rosario et al. estimated that just 14% of all bacteria used selenium24, 
which would make auranofin a narrow-spectrum treatment. A more recent study 
by Peng et al. estimated this number to be ~33%181, however they took their 
analysis further and divided the bacteria up based on the environment in which they 
were found, i.e. terrestrial environments, aquatic environments and host 
environments. Of the 1754 bacteria identified as having selenium utilization traits, 
just 14.7% were associated with a host environment. It should be noted that  
Peng et al. defined evidence of selenium utilization traits as the presence SelD181, 
so this 14.7% would include bacteria that have SelD, but no other selenium 
utilization traits, such as the other selenoproteins. Peng et al. speculated that these 
bacteria with ‘orphan’ SelD may possess selenium pathways that have not yet been 
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characterised181. Selenium utilization traits are present in all three domains of life, 
and evolutionary analyses suggest that most bacterial lineages have lost their ability 
to use selenium211,214, so it is far more likely that bacteria with orphan SelD have 
lost their other selenium utilization traits and that SelD is a remnant of their 
ancestral selenium use. This would make the number of host related bacteria that 
rely on selenium, and thus would be affected by auranofin, less than 14%, so 
auranofin may still be considered a narrow spectrum treatment for CDI. 
Auranofin has been investigated as an antibiotic for other infections recently, 
including Staphylococcus aureus and Enterococcus faecalis, along with other 
Gram-positive bacteria. Studies by Harbut et al. and Thangmai et al. demonstrated 
that auranofin had good in vitro activity against these organisms, and proposed that 
the mechanism of action was against the redox protein thioredoxin reductase 
(TrxR)215,216 As discussed previously auranofin is known to have an affinity for 
redox proteins such as TrxR163, and that in a number of organism TrxR is a 
selenoprotein211. It is interesting to note that there is evidence both have selenium 
utilization properties211, so activity by targeting selenium cannot be ruled out. 
These two studies also investigated that activity of auranofin against Gram-
negative bacteria. Both studies found limited activity against Gram-negative 
bacteria, suggesting that the bacterial membrane was protecting the bacteria from 
auranofin215,216. This narrows the spectrum of activity to Gram-positive bacteria 
only. 
Treatment of CDI is increasingly challenging. Production of spores leads to 
widespread disease, and emerging resistance to antibiotics contributes to refractory 
and recurrent infections. These factors have placed C. difficile on the CDCs urgent 
public health threat list5. It is clear that new antibiotics are needed for this disease. 
Ideal bacterial therapies need to target essential pathways for efficiency and 
reduced risk of resistance202, and should be narrow spectrum to reduce the 
disruption of the microbiota32,33. They also need to be able to infiltrate the site of 
infection in a high enough concentration to eradicate the pathogen. Additional 
requirements specific to CDI include a reduction in transmission capability (i.e. 
spore production and/or viability) and action against the cytotoxic effects of TcdA 
and TcdB. 
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This study has provided evidence supporting the essential nature of selenium as a 
metabolite for C. difficile, and proposes that using auranofin to limit the 
bioavailability of selenium to C. difficile is a strong therapeutic approach. The drug 
does not act on a molecular target on or within the bacteria, thus strongly reducing 
the likelihood of C. difficile acquiring resistance to this treatment. Auranofin may 
be able to be considered a narrow spectrum antibiotic, as previous studies have 
determined that <14% of all host bacteria utilise selenium. Furthermore, auranofin 
has limited activity against Gram-negative bacteria. Auranofin also has ideal 
pharmacokinetic properties for CDI treatment, as up to 85% of the administered 
dose would make it to the distal colon, the site of infection for C. difficile. The in 
vitro and in vivo aspects to this study have demonstrated that auranofin can 
effectively eliminate vegetative C. difficile cell viability as well as affect spore 
production and/or viability, thus eliminating the infection and potentially 
minimising transmission. Auranofin can also protect Vero cells and mice from the 
cytotoxic activity of TcdB, thus potentially preventing symptoms such as diarrhoea, 
intestinal inflammation and intestinal damage that are typically caused by this 
infection. Furthermore, auranofin is a repurposed drug, meaning it has been 
approved for another disease and is now off-license, so the cost is significantly 
reduced. 
Limitations of this study are primarily due to time constraints. These limitations 
include no in vitro data to support the in silico identification of selenoproteins, the 
space limitations within the anaerobic chamber for the in vitro growth assays, as 
well as only doing a preliminary in vivo investigation. Future studies will address 
these limitations, as well as further investigate the activity of auranofin on both C. 
difficile toxins and spores. 
In conclusion, auranofin is a strong candidate for the treatment of CDI due to its 
ability to limit the bioavailability of selenium. The data presented here strongly 
supports further investigations including in vivo animal trials, before proceeding to 
human clinical trials. With increasing failure rates of the current treatments and the 
alternatives deemed expensive, invasive and risky, auranofin may be the ideal 
treatment for CDI as it appears to be effective, easy to administer and cost effective. 
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7. Appendix 1 
Clostridium difficile genomes from NCBI used for analysis of gene 
conservation. 
Genome NCBI Accession 
Clostridium difficile E28 genomic scaffold, 1851_171, whole genome 
shotgun sequence  
NZ_HF923795.1  
Clostridium difficile E7 genomic scaffold, 1839_235, whole genome 
shotgun sequence  
NZ_HF929526.1  
Clostridium difficile E9 genomic scaffold, 1845_204, whole genome 
shotgun sequence  
NZ_HF929904.1  
Clostridium difficile T17 genomic scaffold, 1843_295, whole genome 
shotgun sequence  
NZ_HF925065.1  
Clostridium difficile E14 genomic scaffold, 1848_175, whole genome 
shotgun sequence  
NZ_HF923480.1  
Clostridium difficile T6 genomic scaffold, 1856_217, whole genome 
shotgun sequence  
NZ_HF922885.1  
Clostridium difficile T15 genomic scaffold, 1842_357, whole genome 
shotgun sequence  
NZ_HF928152.1  
Clostridium difficile E25 genomic scaffold, 1838_260, whole genome 
shotgun sequence  
NZ_HF929039.1  
Clostridium difficile T61 genomic scaffold, 2338_59, whole genome 
shotgun sequence  
NZ_HF930132.1  
Clostridium difficile T19 genomic scaffold, 1853_160, whole genome 
shotgun sequence  
NZ_HF924058.1  
Clostridium difficile T3 genomic scaffold, 1859_180, whole genome 
shotgun sequence  
NZ_HF926414.1  
Clostridium difficile T42 genomic scaffold, 2340_70, whole genome 
shotgun sequence  
NZ_HF933940.1  
Clostridium difficile E24 genomic scaffold, 2339_46, whole genome 
shotgun sequence  
NZ_HF927455.1  
Clostridium difficile E19 genomic scaffold, 1849_210, whole genome 
shotgun sequence  
NZ_HF930365.1  
Clostridium difficile T22 genomic scaffold, 1855_190, whole genome 
shotgun sequence  
NZ_HF924628.1  
Clostridium difficile E16 genomic scaffold, 2337_72, whole genome 
shotgun sequence  
NZ_HF927756.1  
Clostridium difficile CD002 genomic scaffold, 2335_51, whole genome 
shotgun sequence  
NZ_HF929271.1  
Clostridium difficile E13 genomic scaffold, 1847_143, whole genome 
shotgun sequence  
NZ_HF925362.1  
Peptoclostridium difficile 840 gcd840.contig.118, whole genome shotgun 
sequence  
NZ_AVIN01000119
.1  
Peptoclostridium difficile CD39 gcdCD39.contig.119, whole genome 
shotgun sequence  
NZ_AVGS0100012
0.1  
Clostridioides difficile isolate IT1118, whole genome shotgun sequence  
NZ_FAXM0100001
2.1  
Peptoclostridium difficile P7 gcdP7.contig.161, whole genome shotgun 
sequence  
NZ_AVLQ0100015
6.1  
Peptoclostridium difficile Y202 gcdY202.contig.217, whole genome 
shotgun sequence  
NZ_AVKY0100021
6.1  
Peptoclostridium difficile Y165 gcdY165.contig.278, whole genome 
shotgun sequence  
NZ_AVKV0100026
7.1  
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Peptoclostridium difficile DA00193 gcdDA00193.contig.49, whole genome 
shotgun sequence  
NZ_AVJO01000049
.1  
Peptoclostridium difficile DA00149 gcdDA00149.contig.68, whole genome 
shotgun sequence  
NZ_AVJF01000068
.1  
Peptoclostridium difficile DA00129 gcdDA00129.contig.54, whole genome 
shotgun sequence  
NZ_AVIY01000054
.1  
Peptoclostridium difficile 842 gcd842.contig.115, whole genome shotgun 
sequence  
NZ_AVIO01000116
.1  
Peptoclostridium difficile CD200 gcdCD200.contig.179, whole genome 
shotgun sequence  
NZ_AVIF01000164
.1  
Peptoclostridium difficile CD175 gcdCD175.contig.457, whole genome 
shotgun sequence  
NZ_AVIB01000444
.1  
Peptoclostridium difficile CD22 gcdCD22.contig.121, whole genome 
shotgun sequence  
NZ_AVGP0100012
2.1  
Peptoclostridium difficile CD3 gcdCD3.contig.229, whole genome shotgun 
sequence  
NZ_AVGI01000222
.1  
Clostridioides difficile strain LIBA-5719 .11940_2_38.2, whole genome 
shotgun sequence  
NZ_JXBQ01000002
.1  
Clostridioides difficile strain LIBA-5701 .11940_2_22.1, whole genome 
shotgun sequence  
NZ_JXBP01000001
.1  
Clostridioides difficile strain LIBA-5704 contig.11940_2_24.1, whole 
genome shotgun sequence  
NZ_JXCP01000001
.1  
Clostridioides difficile strain LIBA-5734 .11940_2_42.2, whole genome 
shotgun sequence  
NZ_JXBR01000002
.1  
Clostridioides difficile strain F17xCD13A, whole genome shotgun sequence  
NZ_CCEV0100007
8.1  
Clostridioides difficile strain CII7xCD13A, whole genome shotgun 
sequence  
NZ_CCDW0100000
1.1  
Clostridioides difficile strain LIBA-5784 .11940_2_72.3, whole genome 
shotgun sequence  
NZ_JXBS01000003
.1  
Peptoclostridium difficile P53 gcdP53.contig.30, whole genome shotgun 
sequence  
NZ_AWZO0100003
1.1  
Peptoclostridium difficile F665 gcdF665.contig.35, whole genome shotgun 
sequence  
NZ_AWZN0100003
6.1  
Peptoclostridium difficile P68 gcdP68.contig.41, whole genome shotgun 
sequence  
NZ_AWZM010000
41.1  
Peptoclostridium difficile P64 gcdP64.contig.40, whole genome shotgun 
sequence  
NZ_AWZL0100004
1.1  
Peptoclostridium difficile P37 gcdP37.contig.43, whole genome shotgun 
sequence  
NZ_AWZK0100004
4.1  
Peptoclostridium difficile P33 gcdP33.contig.34, whole genome shotgun 
sequence  
NZ_AWZI0100003
5.1  
Peptoclostridium difficile DA00130 gcdDA00130.contig.93, whole genome 
shotgun sequence  
NZ_AWZH0100009
3.1  
Peptoclostridium difficile F601 gcdF601.contig.24, whole genome shotgun 
sequence  
NZ_AVNH0100002
5.1  
Peptoclostridium difficile P77 gcdP77.contig.38, whole genome shotgun 
sequence  
NZ_AVNA0100003
9.1  
Peptoclostridium difficile P75 gcdP75.contig.36, whole genome shotgun 
sequence  
NZ_AVMZ0100003
7.1  
Peptoclostridium difficile P74 gcdP74.contig.25, whole genome shotgun 
sequence  
NZ_AVMY0100002
6.1  
Peptoclostridium difficile P73 gcdP73.contig.33, whole genome shotgun 
sequence  
NZ_AVMX0100003
4.1  
Peptoclostridium difficile P71 gcdP71.contig.39, whole genome shotgun 
sequence  
NZ_AVMW010000
40.1  
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Peptoclostridium difficile P72 gcdP72.contig.30, whole genome shotgun 
sequence  
NZ_AVMV0100003
1.1  
Peptoclostridium difficile P70 gcdP70.contig.34, whole genome shotgun 
sequence  
NZ_AVMU0100003
5.1  
Peptoclostridium difficile P69 gcdP69.contig.32, whole genome shotgun 
sequence  
NZ_AVMT0100003
3.1  
Peptoclostridium difficile P78 gcdP78.contig.41, whole genome shotgun 
sequence  
NZ_AVMS0100004
2.1  
Peptoclostridium difficile P61 gcdP61.contig.39, whole genome shotgun 
sequence  
NZ_AVMR0100004
0.1  
Peptoclostridium difficile P59 gcdP59.contig.39, whole genome shotgun 
sequence  
NZ_AVMQ0100004
0.1  
Peptoclostridium difficile P49 gcdP49.contig.28, whole genome shotgun 
sequence  
NZ_AVMN0100002
9.1  
Peptoclostridium difficile P48 gcdP48.contig.41, whole genome shotgun 
sequence  
NZ_AVMM010000
42.1  
Peptoclostridium difficile P46 gcdP46.contig.41, whole genome shotgun 
sequence  
NZ_AVML0100004
1.1  
Peptoclostridium difficile P45 gcdP45.contig.33, whole genome shotgun 
sequence  
NZ_AVMK0100003
4.1  
Peptoclostridium difficile P42 gcdP42.contig.37, whole genome shotgun 
sequence  
NZ_AVMJ0100003
8.1  
Peptoclostridium difficile P32 gcdP32.contig.30, whole genome shotgun 
sequence  
NZ_AVMG0100003
0.1  
Peptoclostridium difficile P31 gcdP31.contig.34, whole genome shotgun 
sequence  
NZ_AVMF0100003
5.1  
Peptoclostridium difficile P30 gcdP30.contig.34, whole genome shotgun 
sequence  
NZ_AVME0100003
5.1  
Peptoclostridium difficile P29 gcdP29.contig.40, whole genome shotgun 
sequence  
NZ_AVMD0100004
1.1  
Peptoclostridium difficile P24 gcdP24.contig.44, whole genome shotgun 
sequence  
NZ_AVMA0100004
4.1  
Peptoclostridium difficile P23 gcdP23.contig.29, whole genome shotgun 
sequence  
NZ_AVLZ0100003
0.1  
Peptoclostridium difficile P21 gcdP21.contig.38, whole genome shotgun 
sequence  
NZ_AVLY0100003
9.1  
Peptoclostridium difficile P20 gcdP20.contig.41, whole genome shotgun 
sequence  
NZ_AVLX0100004
2.1  
Peptoclostridium difficile P19 gcdP19.contig.40, whole genome shotgun 
sequence  
NZ_AVLW0100004
1.1  
Peptoclostridium difficile P13 gcdP13.contig.34, whole genome shotgun 
sequence  
NZ_AVLU0100003
4.1  
Peptoclostridium difficile P9 gcdP9.contig.107, whole genome shotgun 
sequence  
NZ_AVLS0100010
7.1  
Peptoclostridium difficile P8 gcdP8.contig.138, whole genome shotgun 
sequence  
NZ_AVLR0100013
1.1  
Peptoclostridium difficile P5 gcdP5.contig.131, whole genome shotgun 
sequence  
NZ_AVLO0100013
1.1  
Peptoclostridium difficile P3 gcdP3.contig.158, whole genome shotgun 
sequence  
NZ_AVLN0100012
7.1  
Peptoclostridium difficile P2 gcdP2.contig.143, whole genome shotgun 
sequence  
NZ_AVLM0100014
4.1  
Peptoclostridium difficile Y401 gcdY401.contig.137, whole genome 
shotgun sequence  
NZ_AVLK0100013
8.1  
Peptoclostridium difficile Y381 gcdY381.contig.43, whole genome shotgun 
sequence  
NZ_AVLI01000044
.1  
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Peptoclostridium difficile Y358 gcdY358.contig.63, whole genome shotgun 
sequence  
NZ_AVLH0100006
4.1  
Peptoclostridium difficile Y266 gcdY266.contig.132, whole genome 
shotgun sequence  
NZ_AVLC0100013
3.1  
Peptoclostridium difficile Y247 gcdY247.contig.25, whole genome shotgun 
sequence  
NZ_AVLB0100002
6.1  
Peptoclostridium difficile Y231 gcdY231.contig.31, whole genome shotgun 
sequence  
NZ_AVLA0100003
2.1  
Peptoclostridium difficile Y21 gcdY21.contig.139, whole genome shotgun 
sequence  
NZ_AVKS0100014
0.1  
Peptoclostridium difficile F253 gcdF253.contig.323, whole genome shotgun 
sequence  
NZ_AVKO0100030
9.1  
Peptoclostridium difficile F249 gcdF249.contig.80, whole genome shotgun 
sequence  
NZ_AVKN0100008
1.1  
Peptoclostridium difficile F152 gcdF152.contig.13, whole genome shotgun 
sequence  
NZ_AVKM0100001
3.1  
Peptoclostridium difficile DA00313 gcdDA00313.contig.82, whole genome 
shotgun sequence  
NZ_AVKL0100008
2.1  
Peptoclostridium difficile genome assembly CD630DERM, chromosome : 1  NZ_LN614756.1  
Peptoclostridium difficile 630, complete genome  NZ_CP010905.1  
Clostridioides difficile strain G46, whole genome shotgun sequence  
NZ_CDND0100000
1.1  
Peptoclostridium difficile P25 gcdP25.contig.17, whole genome shotgun 
sequence  
NZ_AVMB0100001
8.1  
Peptoclostridium difficile DA00261 gcdDA00261.contig.11, whole genome 
shotgun sequence  
NZ_AVKE0100001
2.1  
Peptoclostridium difficile DA00244 gcdDA00244.contig.9, whole genome 
shotgun sequence  
NZ_AVKA0100001
0.1  
Peptoclostridium difficile DA00203 gcdDA00203.contig.10, whole genome 
shotgun sequence  
NZ_AVJS01000011
.1  
Peptoclostridium difficile strain 08ACD0030, complete genome  NZ_CP010888.1  
Peptoclostridium difficile genome assembly NCTC13307, chromosome : 1  NZ_LN831030.1  
Peptoclostridium difficile CD26A54_S contig6, whole genome shotgun 
sequence  
NZ_AMDL0100000
6.1  
Peptoclostridium difficile CD26A54_R contig4, whole genome shotgun 
sequence  
NZ_AMDM010000
04.1 
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8. Appendix 2 
SECIS elements from Clostridium difficile 630 genome identified 
using in silico methods. 
 
Selenoprotein 
name 
30S Ribosomal protein S1 
(RpsA) 
Level of 
conservation 
100% 
Functional class 
Translation, ribosomal 
structure and biogenesis 
SECIS length 54 nt 
Length UGA to 
apical loop 
32 nt 
Upper stem 8 bp 
Upper stem U 
richness 
50% 
Apical loop 3 nt 
 
Selenoprotein 
name 
4-aminobutyrate 
aminotransferase (GabT) 
Level of 
conservation 
100% 
Functional class 
Amino acid transport and 
metabolism 
SECIS length 45 nt 
Length UGA to 
apical loop 
25 nt 
Upper stem 6 bp 
Upper stem U 
richness 
33.33% 
Apical loop 6 nt 
 
Selenoprotein 
name 
ABC transporter ATP-
binding protein (LolD) 
Level of 
conservation 
100% 
Functional class 
Signal transduction 
mechanisms 
SECIS length 39 nt 
Length UGA to 
apical loop 
19 nt 
Upper stem 4 bp 
Upper stem U 
richness 
66% 
Apical loop 5 nt 
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Selenoprotein 
name 
ABC-transporte sugar-
family ATP-binding 
protein (SalY) 
Level of 
conservation 
100% 
Functional class 
Signal transduction 
mechanisms 
SECIS length 63 nt 
Length UGA to 
apical loop 
23 nt 
Upper stem 5bp 
Upper stem U 
richness 
660% 
Apical loop 3 nt 
 
Selenoprotein 
name 
Chromosomal replication 
initiation protein 
Level of 
conservation 
100% 
Functional class 
Replication, recombination 
and repair 
SECIS length 52 nt 
Length UGA to 
apical loop 
17 nt 
Upper stem 5 bp 
Upper stem U 
richness 
40% 
Apical loop 5 nt 
 
Selenoprotein 
name 
Acetolactate synthase large 
subunit (IlvB) 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites biosynthesis, 
transport and catabolism 
SECIS length 42 nt 
Length UGA to 
apical loop 
22 nt 
Upper stem 4 bp 
Upper stem U 
richness 
50% 
Apical loop 3 nt 
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Selenoprotein 
name 
Alpha-mannosidase 
Level of 
conservation 
100% 
Functional class 
Carbohydrate transport and 
metabolism 
SECIS length 51 nt 
Length UGA to 
apical loop 
18 nt 
Upper stem 5 bp 
Upper stem U 
richness 
20% 
Apical loop 4 nt 
 
Selenoprotein 
name 
Aminotransferase 
 
Level of 
conservation 
100% 
Functional class 
Amino acid transport and 
metabolism 
SECIS length 63nt 
Length UGA to 
apical loop 
31 nt 
Upper stem 4 bp 
Upper stem U 
richness 
50% 
Apical loop 4 nt 
 
Selenoprotein 
name 
Asparagine synthetase 
(AsnB) 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites biosynthesis, 
transport and catabolism 
SECIS length 39 nt 
Length UGA to 
apical loop 
19 nt 
Upper stem 4 bp 
Upper stem U 
richness 
40% 
Apical loop 3 nt 
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Selenoprotein 
name 
Aspartate aminotransferase 
(AspB) 
Level of 
conservation 
100% 
Functional class 
Amino acid transport and 
metabolism 
SECIS length 48 nt 
Length UGA to 
apical loop 
26 nt 
Upper stem 5 bp 
Upper stem U 
richness 
66.66% 
Apical loop 7 nt 
 
Selenoprotein 
name 
Diguanylate kinase 
signalling protein 
Level of 
conservation 
100% 
Functional class Cell motility 
SECIS length 45 nt 
Length UGA to 
apical loop 
22 nt 
Upper stem 4 bp 
Upper stem U 
richness 
33.33% 
Apical loop 6 nt 
 
Selenoprotein 
name 
DinG family helicase 
(DinG) 
Level of 
conservation 
100% 
Functional class 
Replication, recombination 
and repair 
SECIS length 45 nt 
Length UGA to 
apical loop 
18 nt 
Upper stem 6 nt 
Upper stem U 
richness 
28.57% 
Apical loop 6 nt 
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Selenoprotein 
name 
DNA mismatch repair 
protein (MutL) 
Level of 
conservation 
100% 
Functional class 
Replication, recombination 
and repair 
SECIS length 55 nt 
Length UGA to 
apical loop 
24 nt 
Upper stem 4 bp 
Upper stem U 
richness 
50% 
Apical loop 4 nt 
 
Selenoprotein 
name 
DNA primase (DnaG) 
Level of 
conservation 
100% 
Functional class 
Replication, recombination 
and repair 
SECIS length 50 nt 
Length UGA to 
apical loop 
28 nt 
Upper stem 4 bp 
Upper stem U 
richness 
50% 
Apical loop 4 nt 
 
Selenoprotein 
name 
D-proline reductase (PrdA) 
Level of 
conservation 
100% 
Functional class 
Amino acid transport and 
metabolism 
SECIS length 48 nt 
Length UGA to 
apical loop 
20 nt 
Upper stem 4 bp 
Upper stem U 
richness 
50% 
Apical loop 8 nt 
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Selenoprotein 
name 
Electron transport complex 
protein (RnfC) 
Level of 
conservation 
100% 
Functional class 
Energy production and 
conversion 
SECIS length 42 nt 
Length UGA to 
apical loop 
21 nt 
Upper stem 4 bp 
Upper stem U 
richness 
25% 
Apical loop 6 nt 
 
Selenoprotein 
name 
Glutaminase (GlsA) 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites biosynthesis, 
transport and catabolism 
SECIS length 42 nt 
Length UGA to 
apical loop 
18 nt 
Upper stem 5 bp 
Upper stem U 
richness 
60% 
Apical loop 5 nt 
 
Selenoprotein 
name 
GTP-binding protein 
(LepA) 
Level of 
conservation 
100% 
Functional class Translation 
SECIS length 45 nt 
Length UGA to 
apical loop 
19 nt 
Upper stem 4 bp 
Upper stem U 
richness 
50% 
Apical loop 6 nt 
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Selenoprotein 
name 
HAD superfamily 
hydrolase 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites biosynthesis, 
transport and catabolism 
SECIS length 66 nt 
Length UGA to 
apical loop 
30 nt 
Upper stem 7 bp 
Upper stem U 
richness 
57.14% 
Apical loop 3 nt 
 
Selenoprotein 
name 
Minor head protein 
Level of 
conservation 
100% 
Functional class 
General function 
prediction only 
SECIS length 50 nt 
Length UGA to 
apical loop 
21 nt 
Upper stem 5 bp 
Upper stem U 
richness 
40% 
Apical loop 6 nt 
 
Selenoprotein 
name 
Iron-sulfur binding protein 
Level of 
conservation 
100% 
Functional class 
Cell 
wall/membrane/envelope 
biogenesis 
SECIS length 39 nt 
Length UGA to 
apical loop 
19 nt 
Upper stem 6 bp 
Upper stem U 
richness 
28.57% 
Apical loop 4 nt 
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Selenoprotein 
name 
Isoleucine-tRNA ligase 
(IleS) 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites biosynthesis, 
transport and catabolism 
SECIS length 54 nt 
Length UGA to 
apical loop 
30 nt 
Upper stem 5 bp 
Upper stem U 
richness 
20% 
Apical loop 4 nt 
 
Selenoprotein 
name 
K/Mg/Cd/Cu/Zn/Na/Ca/Na
/H-transporting P-type 
ATPase (ZntA) 
Level of 
conservation 
100% 
Functional class 
Inorganic ion transport and 
metabolism 
SECIS length 39 nt 
Length UGA to 
apical loop 
22 nt 
Upper stem 9 bp 
Upper stem U 
richness 
33.33% 
Apical loop 8 nt 
 
Selenoprotein 
name 
Lipoprotein signal 
peptidase (LspA) 
Level of 
conservation 
100% 
Functional class 
Signal transduction 
mechanisms 
SECIS length 48 nt 
Length UGA to 
apical loop 
21 nt 
Upper stem 9 bp 
Upper stem U 
richness 
30% 
Apical loop 3 nt 
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Selenoprotein 
name 
LysR family 
transcriptional regulator 
(LysR) 
Level of 
conservation 
100% 
Functional class Transcription 
SECIS length 51 nt 
Length UGA to 
apical loop 
30 nt 
Upper stem 4 bp 
Upper stem U 
richness 
16.66% 
Apical loop 5 nt 
 
Selenoprotein 
name 
M24 family peptidase 
(PepP) 
Level of 
conservation 
100% 
Functional class 
Amino acid transport and 
metabolism 
SECIS length 48 nt 
Length UGA to 
apical loop 
28 nt 
Upper stem 6 bp 
Upper stem U 
richness 
33.33% 
Apical loop 5 nt 
 
Selenoprotein 
name 
MATE family drug/sodium 
antiporter (NorM) 
Level of 
conservation 
100% 
Functional class Defence mechanisms 
SECIS length 48 nt 
Length UGA to 
apical loop 
30 nt 
Upper stem 8 bp 
Upper stem U 
richness 
66.66% 
Apical loop 3 nt 
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Selenoprotein 
name 
Putative membrane protein 
Level of 
conservation 
100% 
Functional class 
General function 
prediction only 
SECIS length 54 nt 
Length UGA to 
apical loop 
23 nt 
Upper stem 6 bp 
Upper stem U 
richness 
33.33% 
Apical loop 5 nt 
 
Selenoprotein 
name 
Methionine gamma-lysase 
(MdeA) 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites biosynthesis, 
transport and catabolism 
SECIS length 66 nt 
Length UGA to 
apical loop 
27 nt 
Upper stem 6 bp 
Upper stem U 
richness 
83.33% 
Apical loop 10 nt 
 
Selenoprotein 
name 
Putative methyltransferase 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites biosynthesis, 
transport and catabolism 
SECIS length 57 nt 
Length UGA to 
apical loop 
29 nt 
Upper stem 7 bp 
Upper stem U 
richness 
42.86% 
Apical loop 8 nt 
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Selenoprotein 
name 
Multidrug family ABC transporter/ 
ATP-binding protein/permease 
(MdlB) 
Level of 
conservation 
100% 
Functional class Defence mechanisms 
SECIS length 63 nt 
Length UGA to 
apical loop 
30 nt 
Upper stem 4 bp 
Upper stem U 
richness 
50% 
Apical loop 5 nt 
 
Selenoprotein 
name 
NhaC family Na(+)/H(+) 
antiporter 
Level of 
conservation 
100% 
Functional class 
Inorganic ion transport and 
metabolism 
SECIS length 39 nt 
Length UGA to 
apical loop 
18 nt 
Upper stem 5 bp 
Upper stem U 
richness 
80% 
Apical loop 4 nt 
 
Selenoprotein 
name 
Bifunctional 
nitrilase/nitrile hydralatase 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites biosynthesis, 
transport and catabolism 
SECIS length 39 nt 
Length UGA to 
apical loop 
22 nt 
Upper stem 5 bp 
Upper stem U 
richness 
40% 
Apical loop 4 nt 
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Selenoprotein 
name 
Prolyl-tRNA ligase 
(ProS2) 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites biosynthesis, 
transport and catabolism 
SECIS length 39 nt 
Length UGA to 
apical loop 
20 nt 
Upper stem 4 bp 
Upper stem U 
richness 
20% 
Apical loop 4 nt 
 
Selenoprotein 
name 
PTS system 
lactose/cellobiose-family 
IIC component (CelB) 
Level of 
conservation 
100% 
Functional class 
Carbohydrate transport and 
metabolism 
SECIS length 51 nt 
Length UGA to 
apical loop 
25 nt 
Upper stem 7 bp 
Upper stem U 
richness 
28.51% 
Apical loop 3 nt 
 
Selenoprotein 
name 
PTS system, 
fructose/mannitol-family 
IIC component 
Level of 
conservation 
100% 
Functional class 
Carbohydrate transport and 
metabolism 
SECIS length 57 nt 
Length UGA to 
apical loop 
29 nt 
Upper stem 5 bp 
Upper stem U 
richness 
40% 
Apical loop 8 nt 
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Selenoprotein 
name 
Oligopeptide transporter 
(OPT) 
Level of 
conservation 
100% 
Functional class 
Amino acid transport and 
metabolism 
SECIS length 56 nt 
Length UGA to 
apical loop 
18 nt 
Upper stem 4 bp 
Upper stem U 
richness 
25% 
Apical loop 4 nt 
 
Selenoprotein 
name 
Peptidase, M20D family 
(AgbB) 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites biosynthesis, 
transport and catabolism 
SECIS length 41 nt 
Length UGA to 
apical loop 
19 nt 
Upper stem 6 bp 
Upper stem U 
richness 
33.33% 
Apical loop 6 nt 
 
Selenoprotein 
name 
Peptidase, S9 family 
(DAP2) 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites biosynthesis, 
transport and catabolism 
SECIS length 39 nt 
Length UGA to 
apical loop 
18 nt 
Upper stem 4 bp 
Upper stem U 
richness 
50% 
Apical loop 4 nt 
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Selenoprotein 
name 
Pyruvate phosphate 
dikinase, PEP/pyruvate-
binding 
Level of 
conservation 
100% 
Functional class 
Carbohydrate transport and 
metabolism 
SECIS length 42 nt 
Length UGA to 
apical loop 
19 nt 
Upper stem 5 bp 
Upper stem U 
richness 
40% 
Apical loop 4 nt 
 
Selenoprotein 
name 
Signalling protein 
Level of 
conservation 
100% 
Functional class 
Signal transduction 
mechanisms 
 
SECIS length 42 nt 
Length UGA to 
apical loop 
21 nt 
Upper stem 4 bp 
Upper stem U 
richness 
50% 
Apical loop 3 nt 
 
Selenoprotein 
name 
Sodium:solute symporter 
Level of 
conservation 
100% 
Functional class 
Inorganic ion transport and 
metabolism 
SECIS length 54 nt 
Length UGA to 
apical loop 
33 nt 
Upper stem 4 bp 
Upper stem U 
richness 
60% 
Apical loop 4 nt 
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Selenoprotein 
name 
Spore cortex-lytic 
hydrolase (SleB) 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites biosynthesis, 
transport and catabolism 
SECIS length 54 nt 
Length UGA to 
apical loop 
20 nt 
Upper stem 6 bp 
Upper stem U 
richness 
66.66% 
Apical loop 8 nt 
 
Selenoprotein 
name 
Thioredoxin-disulfide 
reductase (TrxB1) 
Level of 
conservation 
100% 
Functional class 
Post-translational 
modification, protein 
turnover, and chaperones 
SECIS length 39 nt 
Length UGA to 
apical loop 
19 nt 
Upper stem 4 bp 
Upper stem U 
richness 
20% 
Apical loop 6 nt 
 
Selenoprotein 
name 
Thiosulfate 
sulfurtransferase (SseA) 
Level of 
conservation 
100% 
Functional class 
Inorganic ion transport and 
metabolism 
SECIS length 42 nt 
Length UGA to 
apical loop 
19 nt 
Upper stem 7 bp 
Upper stem U 
richness 
71.43% 
Apical loop 8 nt 
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Selenoprotein 
name 
Type II secretion system 
protein (PulF) 
Level of 
conservation 
100% 
Functional class 
Intracellular trafficking, 
secretion and vesicular 
transport 
SECIS length 51 nt 
Length UGA to 
apical loop 
18 nt 
Upper stem 5 bp 
Upper stem U 
richness 
20% 
Apical loop 4 nt 
 
Selenoprotein 
name 
UDP-glycosyltransferase, 
MGT subfamily 
Level of 
conservation 
100% 
Functional class 
Carbohydrate transport and 
metabolism 
SECIS length 57 nt 
Length UGA to 
apical loop 
28 nt 
Upper stem 9 bp 
Upper stem U 
richness 
44.44% 
Apical loop 5 nt 
 
Selenoprotein 
name 
UvrABC system protein A 
Level of 
conservation 
100% 
Functional class 
Replication, recombination 
and repair 
SECIS length 54 nt 
Length UGA to 
apical loop 
17 nt 
Upper stem 7 bp 
Upper stem U 
richness 
71.43% 
Apical loop 7 nt 
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Selenoprotein 
name 
Queuine tRNA-
ribosyltransferase (Tgt) 
Level of 
conservation 
100% 
Functional class 
Replication, recombination 
and repair 
SECIS length 48 nt 
Length UGA to 
apical loop 
23 nt 
Upper stem 6 bp 
Upper stem U 
richness 
57.14% 
Apical loop 4 nt 
 
Selenoprotein 
name 
Selenide water dikinase 
(SelD) 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites biosynthesis, 
transport and catabolism 
SECIS length 45 nt 
Length UGA to 
apical loop 
21 nt 
Upper stem 4 bp 
Upper stem U 
richness 
50% 
Apical loop 3 nt 
 
Selenoprotein 
name 
Sodium/glutamate 
symporter (GltC) 
Level of 
conservation 
100% 
Functional class 
Amino acid transport and 
metabolism 
SECIS length 48 nt 
Length UGA to 
apical loop 
20 nt 
Upper stem 5 bp 
Upper stem U 
richness 
60% 
Apical loop 6 nt 
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Selenoprotein 
name 
Spore maturation protein B 
(SpmB) 
Level of 
conservation 
100% 
Functional class 
Cell 
wall/membrane/envelope 
biogenesis 
SECIS length 54 nt 
Length UGA to 
apical loop 
26 nt 
Upper stem 4 bp 
Upper stem U 
richness 
40% 
Apical loop 4 nt 
 
Selenoprotein 
name 
Threonine synthase (ThrC) 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
SECIS length 51 nt 
Length UGA to 
apical loop 
18 nt 
Upper stem 5 bp 
Upper stem U 
richness 
40% 
Apical loop 6 nt 
 
Selenoprotein 
name 
Transcription 
antiterminator, PTS operon 
regulator 
Level of 
conservation 
100% 
Functional class Transcription 
SECIS length 51 nt 
Length UGA to 
apical loop 
26 nt 
Upper stem 5 bp 
Upper stem U 
richness 
42.86% 
Apical loop 3 nt 
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Selenoprotein 
name 
C4-dicarboxylate 
anaerobic carrier (YfcC) 
Level of 
conservation 
100% 
Functional class 
Inorganic ion transport and 
metabolism 
SECIS length 48 nt 
Length UGA to 
apical loop 
18 nt 
Upper stem 10 bp with bulged U+30 
Upper stem U 
richness 
83.33% 
Apical loop 8 nt 
 
Selenoprotein 
name 
Exonuclease ABC subunit 
A (UvrA) 
Level of 
conservation 
100% 
Functional class 
Replication, recombination 
and repair 
SECIS length 54 nt 
Length UGA to 
apical loop 
23 nt 
Upper stem 3 bp 
Upper stem U 
richness 
37.50% 
Apical loop 10 nt 
 
Selenoprotein 
name 
Glycine reductase complex 
component A (GrdA) 
Level of 
conservation 
100% 
Functional class 
Amino acid transport and 
metabolism: Energy production 
and conversion 
SECIS length 45 nt 
Length UGA to 
apical loop 
16 nt 
Upper stem 3 bp 
Upper stem U 
richness 
50% 
Apical loop 6 nt 
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Selenoprotein 
name 
Multidrug family ABC 
transporter permease 
Level of 
conservation 
100% 
Functional class Defence mechanisms 
SECIS length 45 nt 
Length UGA to 
apical loop 
20 nt 
Upper stem 10 bp with bulged U+18 
Upper stem U 
richness 
50% 
Apical loop 8 nt 
 
Selenoprotein 
name 
23s ribosomal RNA (23s-
rRNA) 
Level of 
conservation 
100% 
Functional class 
Translation, ribosomal 
structure and biogenesis 
SECIS length 45 nt 
Length UGA to 
apical loop 
21 nt 
Upper stem 3 bp 
Upper stem U 
richness 
25% 
Apical loop 6 nt 
Selenoprotein 
name 
Two-component sensor 
histidine kinase (OmpR) 
Level of 
conservation 
100% 
Functional class 
Signal transduction 
mechanisms 
SECIS length 51 nt 
Length UGA to 
apical loop 
26 nt 
Upper stem 8 bp with bulged C+37 
Upper stem U 
richness 
50% 
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Apical loop 7 nt 
 
Selenoprotein 
name 
Two-component response 
regulator 
Level of 
conservation 
100% 
Functional class Transcription 
SECIS length 51 nt 
Length UGA to 
apical loop 
23 nt 
Upper stem 11 bp with bulged U+37 
Upper stem U 
richness 
83.33% 
Apical loop 7 nt 
 
Selenoprotein 
name 
Argininosuccinate synthase 
Level of 
conservation 
Very high 
Functional class 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
SECIS length 48 nt 
Length UGA to 
apical loop 
25 nt 
Upper stem 5 bp 
Upper stem U 
richness 
20% 
Apical loop 6 nt 
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Selenoprotein 
name 
Site-specific recombinase 
Level of 
conservation 
Very high 
Functional class 
Replication, recombination 
and repair 
SECIS length 47 nt 
Length UGA to 
apical loop 
28 nt 
Upper stem 4 bp 
Upper stem U 
richness 
25% 
Apical loop 5 nt 
 
Selenoprotein 
name 
ABC transporter permease 
Level of 
conservation 
Very high 
Functional class 
Inorganic ion transport and 
metabolism 
SECIS length 48 nt 
Length UGA to 
apical loop 
21 nt 
Upper stem 7 bp 
Upper stem U 
richness 
28.57% 
Apical loop 3 nt 
 
Selenoprotein 
name 
Membrane protein 
Level of 
conservation 
Very high 
Functional class 
General function 
prediction only 
SECIS length 39 nt 
Length UGA to 
apical loop 
22 nt 
Upper stem 5 bp 
Upper stem U 
richness 
60% 
Apical loop 5 nt 
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Selenoprotein 
name 
Transcriptional regulator, 
Xylose repressor (XylR) 
Level of 
conservation 
Very high 
Functional class Transcription 
SECIS length 51 nt 
Length UGA to 
apical loop 
16 nt 
Upper stem 3 bp 
Upper stem U 
richness 
33.33% 
Apical loop 10 nt 
 
Selenoprotein 
name 
Xylose kinase (XylB) 
Level of 
conservation 
Very high 
Functional class 
Carbohydrate transport and 
metabolism 
SECIS length 48 nt 
Length UGA to 
apical loop 
25 nt 
Upper stem 12 bp with bulged C+35 
Upper stem U 
richness 
41.66% 
Apical loop 7 nt 
 
Selenoprotein 
name 
Glycine reductase complex 
component B subunit 
gamma 
Level of 
conservation 
High 
Functional class 
Amino acid transport and 
metabolism; Energy 
production and conversion 
SECIS length 39 nt 
Length UGA to 
apical loop 
18 nt 
Upper stem 7 bp 
Upper stem U 
richness 
42.86% 
Apical loop 3 nt 
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Selenoprotein 
name 
Phage tail fiber protein 
Level of 
conservation 
High 
Functional class 
General function 
prediction only 
SECIS length 56 nt 
Length UGA to 
apical loop 
26 nt 
Upper stem 7 bp 
Upper stem U 
richness 
42.86% 
Apical loop 3 nt 
 
Selenoprotein 
name 
Amidohydrolase 
Level of 
conservation 
High 
Functional class 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
SECIS length 66 nt 
Length UGA to 
apical loop 
36 nt 
Upper stem 4 bp 
Upper stem U 
richness 
25% 
Apical loop 4 nt 
 
Selenoprotein 
name 
Transcriptional regulator, 
TetR family (TetR_N) 
Level of 
conservation 
High 
Functional class Transcription 
SECIS length 48 nt 
Length UGA to 
apical loop 
23 nt 
Upper stem 5 bp 
Upper stem U 
richness 
40% 
Apical loop 3 nt 
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Selenoprotein 
name 
Putative phage DNA-
binding protein* (YjcR) 
Level of 
conservation 
High 
Functional class 
General function 
prediction only 
SECIS length 39 nt 
Length UGA to 
apical loop 
18 nt 
Upper stem 7 bp 
Upper stem U 
richness 
14.29% 
Apical loop 5 nt 
 
Selenoprotein 
name 
Replication initiation 
factor Tn916-like, CTn7-
Orf27 
Level of 
conservation 
High 
Functional class 
Replication, recombination 
and repair 
SECIS length 56 nt 
Length UGA to 
apical loop 
26 nt 
Upper stem 7 bp 
Upper stem U 
richness 
66.66% 
Apical loop 3 nt 
 
Selenoprotein 
name 
Pyrroline-5-carboxylate 
reductase (ProC2) 
Level of 
conservation 
High 
Functional class 
Amino acid transport and 
metabolism 
SECIS length 45 nt 
Length UGA to 
apical loop 
19 nt 
Upper stem 9 bp with bulged G28 
Upper stem U 
richness 
37.5% 
Apical loop 4 nt 
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Selenoprotein 
name 
Conjugative transposon 
protein (TpcC) 
Level of 
conservation 
High 
Functional class 
General function 
prediction only 
SECIS length 45 nt 
Length UGA to 
apical loop 
24 nt 
Upper stem 5 bp 
Upper stem U 
richness 
40% 
Apical loop 3 nt 
 
Selenoprotein 
name 
PTS system lichenan-
specific IIC component 
(LicC) 
Level of 
conservation 
Moderate-high 
Functional class 
Carbohydrate transport and 
metabolism 
SECIS length 42 nt 
Length UGA to 
apical loop 
17 nt 
Upper stem 4 bp 
Upper stem U 
richness 
50% 
Apical loop 4 nt 
 
Selenoprotein 
name 
ATPase 
Level of 
conservation 
Moderate-high 
Functional class 
Inorganic ion transport and 
metabolism 
SECIS length 42 nt 
Length UGA to 
apical loop 
22 nt 
Upper stem 7 bp 
Upper stem U 
richness 
14.29% 
Apical loop 6 nt 
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Selenoprotein 
name 
Cell surface protein 
Level of 
conservation 
Moderate-high 
Functional class Extracellular structures 
SECIS length 45 nt 
Length UGA to 
apical loop 
29 nt 
Upper stem 11 bp with bulged A+26 
Upper stem U 
richness 
36.36% 
Apical loop 4 nt 
 
Selenoprotein 
name 
Cobalt-specific ABC 
transporter permease 
(EcfT) 
Level of 
conservation 
Moderate 
Functional class 
Inorganic ion transport and 
metabolism 
SECIS length 51 nt 
Length UGA to 
apical loop 
18 nt 
Upper stem 10 bp with bulged C16 
Upper stem U 
richness 
40% 
Apical loop 7 nt 
 
Selenoprotein 
name 
DNA/RNA helicase 
Level of 
conservation 
Moderate 
Functional class 
Replication, recombination 
and repair 
SECIS length 48 nt 
Length UGA to 
apical loop 
20 nt 
Upper stem 5 bp 
Upper stem U 
richness 
60% 
Apical loop 7 nt 
APPENDIX 2 
 
155 
 
Selenoprotein 
name 
Putative hydrolase 
Level of 
conservation 
Moderate-low 
Functional class 
Secondary metabolites biosynthesis, 
transport and catabolism 
SECIS length 48 nt 
Length UGA to 
apical loop 
30 nt 
Upper stem 4 bp 
Upper stem U 
richness 
25% 
Apical loop 5 nt 
 
Selenoprotein 
name 
Conjugative transposon 
protein (Spr) 
Level of 
conservation 
Moderate-low 
 
Functional class 
General function 
prediction only 
 
SECIS length 54 nt 
Length UGA to 
apical loop 
21 nt 
Upper stem 6 bp 
Upper stem U 
richness 
16.66% 
Apical loop 4 nt 
 
Selenoprotein 
name 
Conjugative transposon 
protein 
Level of 
conservation 
Low 
Functional class 
General function 
prediction only 
SECIS length 39 nt 
Length UGA to 
apical loop 
21 nt 
Upper stem 8 bp 
Upper stem U 
richness 
50% 
Apical loop 7 nt 
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Selenoprotein 
name 
Cell wall hydrolase 
Level of 
conservation 
Low 
Functional class 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
SECIS length 51 nt 
Length UGA to 
apical loop 
29 nt 
Upper stem 4 bp 
Upper stem U 
richness 
25% 
Apical loop 8 nt 
 
Selenoprotein 
name 
Cell division 
FtsK/SpoIIIE-family 
protein 
Level of 
conservation 
Low 
Functional class 
Cell cycle control, cell 
division and chromosome 
partitioning 
SECIS length 39 nt 
Length UGA to 
apical loop 
16 nt 
Upper stem 9 bp 
Upper stem U 
richness 
60% 
Apical loop 6 nt 
 
Selenoprotein 
name 
Membrane protein 
Level of 
conservation 
Low 
Functional class 
General function 
prediction only 
SECIS length 39 nt 
Length UGA to 
apical loop 
18 nt 
Upper stem 12 bp 
Upper stem U 
richness 
16.66% 
Apical loop 4 nt 
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Selenoprotein 
name 
Hydrolase beta-lactamase-
like (GloB) 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
SECIS length 57 nt 
Length UGA to 
apical loop 
23 nt 
Upper stem 5 bp 
Upper stem U 
richness 
0% 
Apical loop 5 nt 
 
Selenoprotein 
name 
Pyruvate 
flavodoxin/ferredoxin 
oxidoreductase subunit 
gamma 
Level of 
conservation 
100% 
Functional class 
Carbohydrate transport and 
metabolism 
SECIS length 48 nt 
Length UGA to 
apical loop 
30 nt 
Upper stem 6 bp 
Upper stem U 
richness 
0% 
Apical loop 5 nt 
 
Selenoprotein 
name 
Deoxyribonuclease 
(DNase) 
Level of 
conservation 
100% 
Functional class 
Replication, recombination 
and repair 
SECIS length 51 nt 
Length UGA to 
apical loop 
26 nt 
Upper stem 4 bp 
Upper stem U 
richness 
0% 
Apical loop 6 nt 
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Selenoprotein 
name 
Polysaccharide deacetylase 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
SECIS length 54 nt 
Length UGA to 
apical loop 
26 nt 
Upper stem 5 bp 
Upper stem U 
richness 
0% 
Apical loop 5 nt 
 
Selenoprotein 
name 
Pyridine nucleotide-
disulfide oxidoreductase 
(Lpd) 
Level of 
conservation 
100% 
Functional class 
Energy production and 
conversion 
SECIS length 45 nt 
Length UGA to 
apical loop 
26 nt 
Upper stem 5 bp 
Upper stem U 
richness 
0% 
Apical loop 8 nt 
 
Selenoprotein 
name 
NADPH-dependent FMN 
reductase (WrbA) 
Level of 
conservation 
100% 
Functional class 
General function 
prediction only 
SECIS length 50 nt 
Length UGA to 
apical loop 
27 nt 
Upper stem 4 bp 
Upper stem U 
richness 
0% 
Apical loop 8 nt 
APPENDIX 2 
 
159 
 
Selenoprotein 
name 
Oxygen-independent 
coproporphyrinogen-III 
oxidase (HemN) 
Level of 
conservation 
100% 
Functional class 
Secondary metabolites 
biosynthesis, transport and 
catabolism 
SECIS length 39 nt 
Length UGA to 
apical loop 
21 nt 
Upper stem 5 bp 
Upper stem U 
richness 
0% 
Apical loop 4 nt 
 
Selenoprotein 
name 
Ribonuclease R (Rnase R) 
Level of 
conservation 
100% 
Functional class 
Translation, ribosomal 
structure and biogenesis 
SECIS length 43 nt 
Length UGA to 
apical loop 
19 nt 
Upper stem 11 bp with bulged A32 
Upper stem U 
richness 
0% 
Apical loop 8 nt 
 
Selenoprotein 
name 
MarR family 
transcriptional regulator 
(EffR) 
Level of 
conservation 
Moderate-low 
Functional class Transcription 
SECIS length 48 nt 
Length UGA to 
apical loop 
19 nt 
Upper stem 8 bp with bulged A13 
Upper stem U 
richness 
0% 
Apical loop 4 nt 
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Selenoprotein 
name 
Cell surface protein 
(Cwp84) 
Level of 
conservation 
High 
Functional class Extracellular structures 
SECIS length 51 nt 
Length UGA to 
apical loop 
25 nt 
Upper stem 4 bp 
Upper stem U 
richness 
0% 
Apical loop 6 nt 
 
Selenoprotein 
name 
Antirestriction protein 
(ArdA) 
Level of 
conservation 
Moderate-low 
Functional class 
General function 
prediction only 
SECIS length 51 nt 
Length UGA to 
apical loop 
29 nt 
Upper stem 4 bp 
Upper stem U 
richness 
0% 
Apical loop 6 nt 
 
Selenoprotein 
name 
Integrase (XerC) 
 
Level of 
conservation 
Low 
Functional class Transcription 
SECIS length 42 nt 
Length UGA to 
apical loop 
30 nt 
Upper stem 5 bp 
Upper stem U 
richness 
0% 
Apical loop 3 nt 
 
